Occlusive Arterial Thrombosis and Thrombolysis by Kim, Dongjune A.





























In Partial Fulfillment 
Of the Requirements for the Degree 












COPYRIGHT © 2020 BY DONGJUNE A. KIM 
 





























Dr. David N. Ku, Advisor 
George W. Woodruff School of Mechanical 
Engineering 
Georgia Institute of Technology 
 Dr. Jorge Di Paola 
Pediatrics 
Washington University School of 




Dr. Andrés J. García 
George W. Woodruff School of 
Mechanical Engineering 
Georgia Institute of Technology 
 Dr. Keith Neeves 
Bioengineering and Pediatrics 




Dr. Yuhang Hu 
George W. Woodruff School of Mechanical 
Engineering 
Georgia Institute of Technology 
  
   















It is surprising that it has already been more than four years since I started the Ph.D. 
program at Georgia Tech. As a mechanical engineer from industry, I had certain 
expectations and goals when I entered the program. Initially, I considered the Ph.D. 
program an extended version of the master’s program and, in my case, a chance to change 
focus from mechanical engineering to bioengineering. However, my experience 
throughout the program has been so much more than what I expected. Of course, the 
journey was not an easy one. I know that I couldn’t have come this far without great lab 
mates, collaborators, friends, and family support, as well as an excellent advisor. 
 Before joining the Ku lab, my career had nothing to do with bioengineering nor 
thrombosis. I still remember being so confused by similar words like thrombus, thrombi, 
and thrombosis, which are now very familiar. However, under Dr. Ku’s guidance, I was 
able to make a smooth transition into the field of bioengineering and thrombosis. Dr. Ku 
has made this journey very special, not only by providing various perspectives on my Ph.D. 
project as a clinician, scientist, mechanical engineer, bioengineer, and entrepreneur but also 
by encouraging me to think about how science advances. He recommended books such as   
The Beginning of Infinity and The Structure of Scientific Revolutions, which inspired me to 
think about current science as a part of big paradigm shifts. His way of advising and 
motivating students was also amazing, and I took notes just in case I have a chance to 
mentor someone in the future. I continue to learn so much from him and know that I will 
retrace his lessons in the future. I would also like to give a special thanks to Seungman 
Park, who introduced me to Dr. Ku and the Ku lab. 
 v 
The Ku lab members – Susan, Joav, Michael, Chris, Leo, Britt, Qing, Patricia, 
Viviana, and Gian – also helped me adapt to the field of bioengineering. For me, this 
adaption involved not only learning about the field but also how to perform experiments. 
In my previous work, I had primarily conducted simulations rather than experiments, and 
I learned a significant amount from Susan and Michael. The reader of this thesis will be 
surprised to find out that most of it is experimental work. Discussions with Chris and Leo 
gave me new insights and questions that motivated me to think in depth. 
Outside the Ku lab, I was very fortunate to have excellent collaborators: Katrina, 
Dr. Di Paola, Dongjing, and Dr. Hu. Certainly, there is a limit to how much one person can 
do with a restricted timeframe. However, through them, I expanded my knowledge and 
interests. I would also like to thank the IBB facility managers who taught me to use a 
variety of equipment – Aqua, Laxmi, Andrew, and Yolande. As I needed blood to work on 
my thesis, I visited the abattoir regularly, and I am particularly thankful to Hollifield farm 
and Riverview farm for giving an extra effort to provide porcine blood. 
Stress can occur for many reasons including a Ph.D. degree, and it is very important 
to learn how to be relax and relieve stress. In my case, I played sports to blow off steam. I 
am grateful to GTKSA basketball, ALTA tennis, and Peach climbing members who gave 
me lasting memories.   
Last but not least, I am grateful to my younger brother, my parents, and my wife. 
People around me always asked me about the fancy shoes I was wearing, and I had to say 
that they are all from my younger brother, Dongsoo. I really feel sorry but appreciative that 
he was left to take care of my parents while I was abroad. My parents, the biggest 
 vi 
supporters of this study, pushed and motivated me to challenge this research. It is inspiring 
to realize how much my parents, especially my farther, care about raising an engineer and 
advancing science. Thinking back on it now, there are few people like my father. I hope 
that my parents like what they read here. Finally, I would like to thank my wife, Dayeon, 
who married me this summer and has supported me throughout a rough period this year. 
Especially over the last few months, she must have had a hard time bearing with me. I am 




TABLE OF CONTENTS 
ACKNOWLEDGEMENTS iv 
LIST OF TABLES x 
LIST OF FIGURES xi 
LIST OF SYMBOLS AND ABBREVIATIONS xxii 
SUMMARY                                                                                                               xxv 
CHAPTER 1. INTRODUCTION 1 
1.1 Arterial Thrombosis 1 
1.2 The Mechanism of SIPA Clot Formation 2 
1.3 Coagulation Clots and SIPA Clots 5 
1.4 Treatments for Arterial Thrombosis 6 
CHAPTER 2. CRITICAL ROLE OF a-GRANULES FOR ARTERIAL 
THROMBOSIS                                                                                                                   9 
2.1 Introduction 9 
2.2 Methods 12 
2.2.1 Computational Fluid Dynamics analysis 12 
2.2.2 Arterial thrombosis model for simulating the occlusion time 12 
2.2.3 Mice 14 
2.2.4 High-shear microfluidic stenosis model 14 
2.2.5 Folts-like arterial stenosis model 16 
2.2.6 Analysis 16 
2.3 Results 17 
2.3.1 Hemodynamic flow through a high shear microfluidic device and stenosed 
mouse carotid artery 17 
2.3.2 Platelet VWF is necessary to form occlusive thrombi 19 
2.3.3 Platelet VWF release induces localized formation of an occlusive thrombi 21 
2.3.4 Occlusive thrombus did not form in the Folts-like arterial stenosis model 
without platelet von Willebrand Factor (Nbeal2-/-) 23 
2.3.5 Platelet von Willebrand Factor is essential for the rapid platelet accumulation 
phase and induces vessel occlusion 24 
2.4 Discussion 26 
2.5 Conclusion 29 
2.6 Acknowledgments 29 
 viii 
CHAPTER 3. THE PERMEABILITY AND MECHANICAL STRENGTH OF A 
SIPA CLOT                                                                                                                 30 
3.1 Introduction 30 
3.2 Methods 34 
3.2.1 In vitro stenotic chambers 34 
3.2.2 In vitro flow loops for SIPA clot generation 35 
3.2.3 Coagulation clot generation 37 
3.2.4 Permeability measurement using Darcy’s law 37 
3.2.5 Multi-channel analysis 39 
3.2.6 Breakage strength measurement 40 
3.2.7 Computational fluid dynamics and finite element analysis 41 
3.2.8 Histology and immunohistochemistry 43 
3.2.9 Scanning electron microscope imaging 43 
3.2.10 Dynamic mechanical analysis 43 
3.2.11 Analysis 44 
3.3 Results 44 
3.3.1 A SIPA clot is more permeable than a coagulation clot 44 
3.3.2 Porous structure of SIPA clot 47 
3.3.3 SIPA clot has greater breakage strength than coagulation clot 48 
3.3.4 A SIPA clot generation in a closed flow loop 49 
3.3.5 Platelets are tightly packed in a SIPA clot 51 
3.3.6 A SIPA clot is VWF-platelet-rich and has a porous structure 64 
3.3.7 A SIPA clot is rich in VWF, especially near the wall 88 
3.3.8 A SIPA clot is stiffer than a coagulation clot 90 
3.3.9 Clot deformation and critical lengths for the arterial occlusion 91 
3.4 Discussion 96 
3.5 Conclusions 102 
3.6 Acknowledgements 103 
CHAPTER 4. THROMBOLYSIS OF ARTERIAL SIPA CLOTS 104 
4.1 Introduction 104 
4.2 Methods 106 
4.2.1 Capillary tube preparation 106 
4.2.2 Collagen coating 106 
4.2.3 Blood collection 106 
4.2.4 Syringe perfusion 107 
4.2.5 Formation and lysis of coagulation clots 108 
4.2.6 Computational Fluid Dynamics analysis 109 
4.2.7 Data analysis 109 
4.3 Results 110 
4.3.1 DiNAC lysed SIPA clots better than NAC 110 
 ix 
4.3.2 Dose response of DiNAC 113 
4.3.3 Thrombolytic efficacy of the other agents on SIPA clots 114 
4.3.4 DiNAC does not lyse fibrin-rich coagulation clots 116 
4.3.5 SIPA clot elongates and break during DiNAC perfusion 119 
4.4 Discussion 121 
4.5 Conclusion 124 
CHAPTER 5. CONCLUSIONS AND FUTURE WORK 125 
APPENDIX A. FOLTS-LIKE ARTERIAL STENOSIS MODEL 127 
APPENDIX B. SIPA CLOT GENERATION PROTOCOL 130 
REFERENCES                                                                                                               134 
 
 x 
LIST OF TABLES 
Table 1 Constants for the RPA phase thrombus growth-rate equation 13 
Table 2 Average values of measured clot parameters and calculated 
permeability 
47 
Table 3 Reynolds number and occlusion time of three high shear chambers 
with constant pressure head driven flow. 
50 
Table 4 Critical clot length for coronary occlusion based on the breakage 
strength of the thrombus. 
95 
Table 5 Thrombolytic agent concentration and replicate number 107 
   
  
 xi 
LIST OF FIGURES 
Figure 1-1 Mechanism for high-shear arterial thrombosis 4 
Figure 1-2 Essential triads for coagulation and SIPA clot formation 6 
Figure 1-3 (A) Thrombolytic therapy using tPA. (B) thrombectomy 
device retrieving a blood clot. 
8 
Figure 2-1 Microfluidic set-up (A) before and (B) after the optimization 
for the minimal blood usage. 
15 
Figure 2-2 (A) Microfluidic set-up optimization using porcine blood 
before mice blood test. (B) Top-down view of blood flow in 
microfluidic channel. (C) Platelet adhesion, (D) SIPA clot 
formation, and (E) occlusion was achieved with 1.5 mL of 
blood. 
15 
Figure 2-3 Hydrodynamic flow characteristics through a high-shear 
microfluidic device and stenosed mouse carotid artery. (A) 
Geometry of the microfluidic model with a stenotic test 
section. (B) Schematic of in vivo experiments showing a 
stenotic region relative to flow direction and flow-probe 
placement. (C) CFD simulations of the microfluidic device. 
Blood flows from left to right. The color contour shows the 
shear strain-rate distribution. The solution shows a maximum 
shear strain rate of > 3,500 s-1 in the stenosis region, while the 
upstream and downstream values are < 1,000 s-1. (D) CFD 
simulation in a stenosed mouse carotid artery. The large 
velocity gradient at the stenotic apex leads to initial shear rates 
that exceed 4,000 s-1. (E) & (F) Thrombus growth was 
predicted using a high-shear thrombosis model by Mehrabadi 
et al. (2016). The shear strain-rate estimation over time during 
high-shear thrombosis formation in a microfluidic assay and 
mouse carotid artery. Min and Max denote for the lower and 
upper confidence limits of the model. 
18 
Figure 2-4 Plasma VWF is sufficient for the initial adhesion of platelets 
to collagen, while locally released platelet VWF is necessary 
for forming the subsequent occlusive thrombi. Representations 
of WT and Nbeal2-/- platelet adhesion and the subsequent 
occlusion during the 8-min perfusion period. The progressive 
accumulation of platelets is observed over time. (A) WT mice 
blood showed rapid and significant platelet adhesion and 
aggregation leading to occlusion. (B) Nbeal2-/- mice blood did 
not form occlusive thrombi during the 8-min observation 
20 
 xii 
period. Occlusive thrombi formed following the addition of 
WT whole blood (Rescue) to adherent Nbeal2-/- platelets on 
collagen. The 1-mm stenosis region is marked with a red line 
under the image. The region of interest (ROI) appears blank 
before the adhesion of platelets (green, DIOC6). The flow 
direction is from left to right. Scale bar, 1,000 µm. (C) 
Normalized fluorescent intensities comparing thrombus 
growth and occlusion in the control WT (n = 6), Nbeal2-/- (n = 
6), and Rescue (n = 3) channels. The initial lag phase is quickly 
proceeded by RPA, demonstrated by a fast increase in thrombus 
size and intensity at approximately 100 seconds for WT whole 
blood and at 515 ± 47 s for Nbeal2-/- + WT whole blood. 
Occlusion occurs at the end of the plot for WT and Nbeal2-/- + 
WT whole blood. No occlusion was observed with Nbeal2-/- 
whole blood alone. A black arrow denotes the time point when 
WT whole blood was added to the Nbeal2-/- channels. All 
images were post-processed and averaged to compare the 
intensity levels in the test sections. (D) Occlusion times in the 
microfluidic device for WT (326 ± 25 s), Nbeal2-/- (no 
occlusion), and Nbeal2-/- + WT (166 ± 48 s) blood. All three 
occlusion times are significantly different from each other (p < 
0.001). 
Figure 2-5 Human SIPA clots forms at upstream regions of stenotic 
section in microfluidics (n = 8). (A) Channel is separated into 
5 ROIs. (B) ROI 1 showed significantly higher normalized 
intensity level compare to the other ROIs (p < 0.0001). ROI 2 
and 3 had a 50% lower intensity level compare to ROI 1. ROI 
0 and 4 had lowest intensity level approximately 10% lower 
than ROI 1. 
22 
Figure 2-6 The platelet VWF induces the localized formation of occlusive 
thrombi. (A) The three ROIs for the microfluidic channel test 
section. (B) Normalized fluorescent intensity level of each ROI 
after an 8-min perfusion for WT (n = 6) and Nbeal2-/- (n = 3), 
and a 5-min perfusion for the Rescue (n = 3). ROI 1 showed a 
significantly higher intensity level with WT (p < 0.001) and 
Rescue (p < 0.01) compared to ROI 2 and 3. There was no 
significant increase in ROI 1 with Nbeal2-/-. (C) & (D) 
Intensity levels of each ROI over perfusion time. The black 
arrow denotes the time point when WT whole blood was added 
to the Nbeal2-/- channels. The intensity level of ROI 1 rapidly 
increased after 80 s for the WT and 20 s for the Rescue. 
22 
Figure 2-7 The absence of platelet VWF prevents occlusive thrombus 
formation in the modified Folts arterial stenosis model. (A) 
Mean blood flow through the carotid artery with an ~50 % 
24 
 xiii 
stenosis (reduction in blood flow) and crush injury. WT mice 
consistently formed an occlusive thrombus in response to the 
stenosis and a crush injury. In contrast, there was no occlusive 
thrombus formation in the carotid artery of the Nbeal2-/- mice 
(n = 7 ± SEOM, p < 0.0001). (B) WT mice formed occlusive 
thrombi at an average time of 330 sec following de-
endothelization of the stenosed vessel. Nbeal2-/- mice were 
unable to form occlusive thrombi in vivo. (n = 7 ± SEOM, p < 
0.0005). (C) Representative macroscopic images of the gross 
anatomy of an excised carotid artery from WT and Nbeal2-/- 
mice. The WT carotid artery features a prominent clot 
(arrowheads) within the longitudinal arterial lumen (outlined), 
suggesting the presence of an occlusion.  There is a clear 
absence of occlusive matter within the lumen of the Nbeal2-/- 
carotid artery (outlined). (D) Carstairs histological staining 
revealed that WT thrombi were primarily composed of 
platelets (the blue material occluding in the lumen). 
Figure 2-8 Comparison of simulated occlusion times against actual 
experimental values.  (A) In vitro microfluidics. (B) In vivo 
mouse carotid artery Folts-like model. 
25 
Figure 3-1 Coagulation blood clot modulus from Johnson et al. (2017) and 
Slaboch et al. (2012). 
33 
Figure 3-2 Geometry of the stenotic chambers: (A) Microfluidic chamber 
(55% stenosis by diameter), (B) Capillary glass tube (ID = 1.5 
mm, 65% stenosis by diameter), and (C) Large glass tube (ID 
= 12 mm, 80% stenosis by diameter). 
35 
Figure 3-3 In vitro flow loops with different flow drivers. A single-path 
flow driven by (A) a constant pressure head or (B) a constant 
flow rate was used with the microfluidic chamber and capillary 
tube to measure clot permeability and breakage strength. (C) A 
closed loop circuit was developed to generate a clot in a large 
stenosis that has diameter greater than 2 mm, in order to 




Parameters from perfusion images for the permeability 
calculation using Darcy’s law. (A) Cuboid porous medium 
modeling the clot in the microfluidic chamber. (B) Cylindrical 
porous medium modeling the clot in the capillary tube. 
38 
Figure 3-5 Outlet mass measured (blue) along the perfusion time in (A) 
the microfluidic chamber and (B) the capillary tube. 
39 
 xiv 
Evaporation at the reservoir surface is reflected, and the 
corrected outlet mass is shown in red line. 
Figure 3-6 Forces acting on an occlusive clot in a stenotic chamber. (A) 
Two-dimensional and (B) three-dimensional views of forces 
and parameters on an occlusive clot. 
41 
Figure 3-7 A porous media CFD model with a clot (light blue) located at 
the stenosis. 
42 
Figure 3-8 A 2-D axisymmetric model for a simulation of clot 
deformation and stress distribution. (A) A fixed support 
boundary condition was applied at the interface between the 
clot and channel wall. Calculated pressure was applied on (B) 
proximal and (C) distal clot surfaces. 
42 
Figure 3-9 Input displacement for DMA of the blood clots. 44 
Figure 3-10 Permeability measurement results of the SIPA clot and 
coagulation clots. Wufsus et al. (2013) measured the 
permeability of coagulation clots with platelet concentrations 
of (1) 61% and (2) 31%. Compared to the coagulation clots, 
the SIPA clots showed significantly higher permeability (p < 
0.05). 
45 
Figure 3-11 SIPA clot growth simulation of (A) the microfluidic chamber 
and (B) the capillary tube showing that the constant pressure 
condition completely occludes the channels, while the constant 
flow condition leaves (A) a gap or (B) a hole at the center. (C) 
SIPA clot permeability with the reflected effect (i.e., gap or 
hole) (*). 
47 
Figure 3-12 Multi-channel analysis result of SIPA clot. (A) Pore diameter 
ranged from 1 to 100 and (B) pore number ranged from 1 to 
10,000. 
48 
Figure 3-13 The SIPA clots showed significantly higher breakage strength 
(* p < 0.05) than the coagulation clots. The presence (n = 3) or 
absence (n = 3) of a collagen surface did not significantly 
impact coagulation clot strength. Whether the stenotic chamber 
was a microfluidic chamber (n = 7) or a capillary tube (n = 7) 
did not significantly changed SIPA clot breakage strength. 
49 
Figure 3-14 (A) Stenosed large glass tube coated with collagen type 1. (B) 
The SIPA clot shown in white formed at the stenosis region. 
(C) The SIPA clot boundary is highlighted in yellow. 
50 
 xv 
Figure 3-15 (A) Flow rate over time from the experiment (red, n = 11) and 
the simulation (blue). (B) Using the average value of the initial 
flow rate, CFD showed a maximum shear rate of 10,083 s-1 at 
the initial stage of perfusion. 
51 
Figure 3-16 (A) A SIPA clot retrieved from the large glass tube was (B) 
formalin fixed and (C) dehydrated using ethanol and cut in half 
to expose cross section. (D) Magnified view of stenotic part of 
the clot. (E) Platelet-rich white region is highlighted in green 
showed mountains of platelet aggregates (white arrows). (F) 
Regions of interest are specified in. 
52 
Figure 3-17 SEM image of the SIPA clot (R1). 53 
Figure 3-18 SEM image of the SIPA clot (R2). 53 
Figure 3-19 SEM image of the SIPA clot (R3). 54 
Figure 3-20 SEM image of the SIPA clot (R4). 54 
Figure 3-21 SEM image of the SIPA clot (A). 55 
Figure 3-22 SEM image of the SIPA clot (A) with high magnification. 55 
Figure 3-23 SEM image of the SIPA clot (B). 56 
Figure 3-24 SEM image of the SIPA clot (B) with high magnification. 56 
Figure 3-25 SEM image of the SIPA clot (C). 57 
Figure 3-26 SEM image of the SIPA clot (C) with high magnification. 57 
Figure 3-27 SEM image of the SIPA clot (D). 58 
Figure 3-28 SEM image of the SIPA clot (D) with high magnification. 58 
Figure 3-29 SEM image of the SIPA clot (E). 59 
Figure 3-30 SEM image of the SIPA clot (E) with high magnification. 59 
Figure 3-31 SEM image of the SIPA clot (F). 60 
Figure 3-32 SEM image of the SIPA clot (F) with high magnification. 60 
Figure 3-33 SEM image of the SIPA clot (G). 61 
Figure 3-34 SEM image of the SIPA clot (G) with high magnification. 61 
 xvi 
Figure 3-35 SEM image of the SIPA clot (H). 62 
Figure 3-36 SEM image of the SIPA clot (H) with high magnification. 62 
Figure 3-37 SEM image of the SIPA clot (I). 63 
Figure 3-38 SEM image of the SIPA clot (I) with high magnification. 63 
Figure 3-39 Unactivated platelet density of each region taken by SEM. 64 
Figure 3-40 Carstairs staining of the SIPA clot in the longitudinal direction. 67 
Figure 3-41 VWF staining of the SIPA clot in the longitudinal direction. 67 
Figure 3-42 (A) Regions of interest from the longitudinal slide (L1-6). (B) 
Approximate locations of the cross sections (T1-8). 
68 
Figure 3-43 Carstairs staining of the SIPA clot in the longitudinal direction  
(L1, 5x magnification). 
68 
Figure 3-44 VWF staining of the SIPA clot in the longitudinal direction  
(L1, 5x magnification). 
69 
Figure 3-45 Carstairs staining of the SIPA clot in the longitudinal direction  
(L1, 40x magnification). 
69 
Figure 3-46 Carstairs staining of the SIPA clot in the longitudinal direction  
(L1, 100x magnification). 
70 
Figure 3-47 Carstairs staining of the SIPA clot in the longitudinal direction 
(L2, 5x magnification). 
70 
Figure 3-48 Carstairs staining of the SIPA clot in the longitudinal direction  
(L2, 40x magnification). 
71 
Figure 3-49 Carstairs staining of the SIPA clot in the longitudinal direction  
(L2, 100x magnification). 
71 
Figure 3-50 Carstairs staining of the SIPA clot in the longitudinal direction  
(L3, 5x magnification). 
72 
Figure 3-51 Carstairs staining of the SIPA clot in the longitudinal direction  
(L2, 40x magnification). 
72 
Figure 3-52 Carstairs staining of the SIPA clot in the longitudinal direction  
(L4, 5x magnification). 
73 
 xvii 
Figure 3-53 Carstairs staining of the SIPA clot in the longitudinal direction  
(L4, 40x magnification). 
73 
Figure 3-54 Carstairs staining of the SIPA clot in the longitudinal direction  
(L4, 100x magnification). 
74 
Figure 3-55 Carstairs staining of the SIPA clot in the longitudinal direction  
(L5, 5x magnification). 
74 
Figure 3-56 VWF staining of the SIPA clot in the longitudinal direction  
(L5, 5x magnification). 
75 
Figure 3-57 Carstairs staining of the SIPA clot in the longitudinal direction  
(L5, 40x magnification). 
75 
Figure 3-58 Carstairs staining of the SIPA clot in the longitudinal direction  
(L5, 100x magnification). 
76 
Figure 3-59 Carstairs staining of the SIPA clot in the longitudinal direction  
(L6, 5x magnification). 
76 
Figure 3-60 Carstairs staining of the SIPA clot in the longitudinal direction  
(L6, 40x magnification). 
77 
Figure 3-61 Carstairs staining of the SIPA clot in the longitudinal direction  
(L6, 100x magnification). 
77 
Figure 3-62 Carstairs staining of the SIPA clot in the transverse direction  
(T1, 5x magnification). 
78 
Figure 3-63 VWF staining of the SIPA clot in the transverse direction  
(T1, 5x magnification). 
78 
Figure 3-64 Carstairs staining of the SIPA clot in the transverse direction  
(T2, 5x magnification). 
79 
Figure 3-65 VWF staining of the SIPA clot in the transverse direction  
(T2, 5x magnification). 
79 
Figure 3-66 Carstairs staining of the SIPA clot in the transverse direction  
(T3, 5x magnification). 
80 
Figure 3-67 VWF staining of the SIPA clot in the transverse direction  
(T3, 5x magnification). 
80 
Figure 3-68 Carstairs staining of the SIPA clot in the transverse direction  
(T4, 5x magnification). 
81 
 xviii 
Figure 3-69 VWF staining of the SIPA clot in the transverse direction  
(T4, 5x magnification). 
81 
Figure 3-70 Carstairs staining of the SIPA clot in the transverse direction  
(T5, 5x magnification). 
82 
Figure 3-71 VWF of the SIPA clot in the transverse direction  
(T5, 5x magnification). 
82 
Figure 3-72 Carstairs staining of the SIPA clot in the transverse direction  
(T6, 5x magnification). 
83 
Figure 3-73 VWF of the SIPA clot in the transverse direction  
(T6, 5x magnification). 
83 
Figure 3-74 Carstairs staining of the SIPA clot in the transverse direction  
(T7, 5x magnification). 
84 
Figure 3-75 VWF staining of the SIPA clot in the transverse direction  
(T7, 5x magnification). 
84 
Figure 3-76 Carstairs staining of the SIPA clot in the transverse direction  
(T8, 5x magnification). 
85 
Figure 3-77 VWF staining of the SIPA clot in the transverse direction  
(T8, 5x magnification). 
85 
Figure 3-78 Carstairs staining of the SIPA clot in the transverse direction  
(T9, 5x magnification). 
86 
Figure 3-79 VWF staining of the SIPA clot in the transverse direction  
(T9, 5x magnification). 
86 
Figure 3-80 Histological analysis of (A) WB and (B) PRP coagulation 
clots, and (C1) a SIPA clot. Color segmentation of the SIPA 
clot displayed (C2) platelets, (C3) fibrins, (C4) RBCs, and (C5) 
void space. (D) Composition of each clot. 
87 
Figure 3-81 VWF staining result for (A) a PRP coagulation clot and (B) a 
SIPA clot (40x magnification). 
88 
Figure 3-82 (A) VWF staining and (B) Carstairs staining of a SIPA clot in 
the transverse direction (Section T6, 10x magnification). 
89 
Figure 3-83 DMA result showing SIPA clot force response to a 0.2 mm 
displacement with 1 Hz frequency. 
90 
 xix 
Figure 3-84 Blood clot compressive modulus measured by DMA. On 
average, clots had an initial height of 1.8 mm. Three different 
displacements were applied on the blood clots ((A): 0.1 mm. 
(B): 0.2 mm. (C): 0.5 mm). 
91 
Figure 3-85 Pressure contour in a stenosed tube with a blood clot. 93 
Figure 3-86 SIPA clot FE result showed maximum deformation of 1.4 mm. 93 
Figure 3-87 SIPA clot FE result showed stress less than its breakage 
strength (4.6 kPa). 
94 
Figure 3-88 Coagulation clot FE result showed maximum deformation of 
3.3 mm. 
94 
Figure 3-89 Coagulation clot FE result showed more than 39% area having 
a stress higher than its breakage strength (675 Pa). 
95 
Figure 3-90 Process of SIPA clot formation in a large glass tube. 102 
Figure 4-1 The in vitro perfusion system for creating platelet-rich, 
occlusive thrombi under arterial (high) shear rates, followed by 
perfusion of known and potential lytic agents. (A) Schematic 
of the arterial flow setup. (B) Close-up of the glass capillary 
tube with stenosis, which is coated with fibrillar collagen prior 
to perfusion. The red box denotes the region of interest. (C) 
Thrombus formation and subsequent perfusion with a PBS 
control, showing no lysis at the end of the experiment. 
108 
Figure 4-2 Perfusion with DiNAC. The thrombus surface area was 
determined by pixel counting and is shown in paired images 
below originals, with the thrombus area highlighted in green. 
(A) 2 mM DiNAC perfusion showing complete (> 95 % 
surface area reduction) lysis in 14 min. (B) 20 mM DiNAC 
perfusion showing complete lysis in 1.5 min. 
111 
Figure 4-3 Perfusion with NAC. The thrombus surface area was 
determined by pixel counting and is shown in paired images 
below originals, with the thrombus area highlighted in green. 
(A) 2 mM NAC perfusion, with minimal lysis (< 20 % surface 
area reduction) after 60 min. (B) 20 mM NAC perfusion after 
60 min, again with minimal lysis even at increased 
concentration. 
112 
Figure 4-4 Perfusion with DiNAC and NAC. (A) Thrombus area 
reduction over time.  PBS is included as a negative control 
(black line).  (B) Thrombus area after 60 min perfusion with 
the indicated agent (x-axis). 2 mM and 20 mM DiNAC cause 
113 
 xx 
significantly more lysis than the control, while neither 
concentration of NAC was more efficacious than PBS. DiNAC 
also was significantly different from NAC at each 
concentration. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p 
< 0.0001. 
Figure 4-5 DiNAC dosage response with concentrations of 0.02 mM, 0.2 
mM, 2 mM, and 20 mM. The * denotes the acidic DiNAC 20 
mM solution. (A) Thrombus area reduction over time. The 
control is shown in black. 0.02 mM DiNAC was not different 
from the control (yellow), and 2 mM DiNAC (orange) had the 
greatest efficacy. (B) Thrombus area after 60 min perfusion 
with increasing concentrations of DiNAC. Concentrations of 
0.2 mM and greater were significantly different from the 
control. Neutralization of DiNAC mitigated variability and 
increased the surface area reduction (20 mM vs. 20* mM). * p 
< 0.05; *** p < 0.001; **** p < 0.0001. 
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Figure 4-6 Thrombolysis with the other agents. The thrombus area is 
highlighted in green. Perfusion with tPA (A), ADAMTS-13 
(B), and abciximab (C) perfusion showed minimal lysis after 
60 min. (D) Thrombus area reduction over time. (E) Thrombus 
area after 60 min perfusion with the indicated agent (x-axis). 
Perfusion of tPA, ADAMTS-13, and abciximab had no effect 
on the white clot, with no differences from the control. 
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Figure 4-7 Lysis results on WB coagulation clots formed under stagnant 
conditions over 48 h (n = 3 per agent). Only tPA showed a large 
decrease in coagulation clot volume. 
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Figure 4-8 Lysis results on PRP coagulation clots formed under stagnant 
conditions over 48 h (n = 3 per agent). Only tPA showed a large 
decrease in coagulation clot volume. 
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Figure 4-9 Change of clot weight with WB (A) and PRP (B) clot in 48 h. 
tPA-lysed clots resulted in changes in weight significantly 
different from baseline after 6 h for WB (A) and 12 h for PRP 
(B) (26 % and 36 % reduction, respectively, **p < 0.01).  
DiNAC, NAC, and ADAMTS-13 had no effect on red clots, 
with no differences from baseline nor control. 
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Figure 4-10 Simulation of flow and force through the stenosis using CFD. 
(A) Structure of a thrombus during elongation and breakage at 
0, 15, and 30 minutes of DiNAC perfusion. Black arrows 
denote points of tether breakage. (B) Computer model of the 
attached thrombus fragments at 15 min. (C) Velocity 
streamlines showing a jet-like flow and recirculation 
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downstream of the elongated thrombus colored in gray. (D) 
Shear strain rate around the thrombus. A maximum shear of 
15,000 s-1 (red) was observed in the throat of stenosis. (E) Drag 
force acting on the thrombi surface. The thrombus 2 fragment 
experiences a maximum force of > 4 nN. 
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SUMMARY 
Occlusive arterial thrombosis in a stenotic vessel can cause the cessation of blood flow to 
the brain or heart, which can result in a patient’s death. Following the incident, the patient 
may be given a thrombolytic agent or undergo a thrombectomy to recanalize the occluded 
vessel and to regain blood flow. The current standard for thrombolytic treatment involves 
the administration of tissue plasminogen activator (tPA), which has shown limited efficacy 
and creates a bleeding risk. 
An arterial thrombus differs from a venous thrombus in terms of both its mechanism 
of formation and composition. The von Willebrand Factor (VWF)-platelet-rich arterial 
thrombus forms by shear induced platelet aggregation (SIPA), and can occlude the vessel 
in harsh hemodynamic environments consisting of high shear rates and high blood 
pressure. It is critical to know what key factors affect the formation of occlusive SIPA 
clots, how these clots stabilize under arterial conditions, and which agents should be used 
for a lysis. The overall goal of this thesis is to investigate these three important aspects of 
arterial thrombosis formed under a pathological high shear. 
VWF is a protein that plays a critical role in forming SIPA clots under high shear 
conditions. Platelet ⍺-granules	contain	50	times	more	concentrated	VWF	compared	to	
plasma	VWF. The role of ⍺-granules	in	forming	occlusive	arterial	thrombi	was	studied	
using	Nbeal2-/-	mice	that	do	not	release	⍺-granules.	Without	⍺-granule	release,	there	
was	no	rapid	platelet	accumulation	and	no	subsequent	channel	occlusion	occurred.	




SIPA	 clots	 formed	 using	 arterial-like	 hemodynamic	 conditions	 in	 vitro	 were	
compared	to	coagulation	clots	generated	under	static	conditions.	SEM images of the 
SIPA clot revealed densely packed platelets, which can be converted into 1.23 billion 
platelets in the total clot. Histological images showed distinctive structural features that 
were different upstream, near the apex, and downstream of the stenosis. The upstream 
region showed mountain-like platelet aggregates protruding to the central lumen that left a 
large hole in the center, while RBCs trapped in valleys. Near the apex, a uniformly dense 
platelet mass formed throughout the lumen to fully occlude the channel. In the upstream 
part of the occlusive mass, platelets were amorphous consistent with activation. In the 
downstream part of the mass, spherical platelets dominated, consistent with no activation. 
The thrombus ended abruptly in the expansion past the throat of the stenosis and did not 
extend to the walls located in the flow separation zone. Measurements of pressure and flow 





Different types of clots may require different thrombolytic agents for lysis and 
vessel recanalization. Five different thrombolytic agents were tested on SIPA and 
coagulation clots in an in vitro model. A fibrinolytic agent, tPA lysed the coagulation clots 
but not the SIPA clots. Meanwhile, a novel thrombolytic agent, N,N’-Diacetyl-L-cystine 
(DiNAC) significantly lysed the SIPA clots without dissolving the coagulation clots. 
 xxvii 
The results of this study may lead to the development of a new antithrombotic agent 
that inhibits formation or release of VWF from ⍺-granules of platelets, thrombectomy 
devices that account for SIPA clot permeability and strength, and a new thrombolytic 
treatment using DiNAC.  
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CHAPTER 1. INTRODUCTION 
1.1 Arterial Thrombosis 
Acute arterial thrombosis is a pathological condition where a blood clot forms in a stenotic 
artery. The clot can interrupt or even stop the blood flow once the clot becomes occlusive. 
Occlusive arterial thrombosis in a carotid or coronary artery can result in an ischemic stroke 
or myocardial infarction, which are the leading causes of death worldwide (Adams, 2003; 
Xu, Murphy, Kochanek, & Arias, 2020).  
Arterial thrombosis begins with plaque development in the arteries, which takes 
place over many decades via the process of atherosclerosis. The plaque narrows the lumen 
of the vessel, generating a stenosis. The stenotic region can have wall shear rates ranging 
from 5,000 to 400,000 s-1, which are much higher than the typical shear rates of  < 1,000 s-
1 in arteries (Bark Jr & Ku, 2010; Shaun P Jackson, 2007). At a certain point, a plaque-cap 
rupture occurs, and the endothelial cell layer can be disturbed to expose its pro-
thrombogenic collagen surface (Davies & Thomas, 1985). The collagen layer provides a 
surface for the von Willebrand Factor (VWF) to tether to and elongate, and for platelets to 
adhere to and aggregate (Santoro, 1981; Savage, Ginsberg, & Ruggeri, 1999). Platelet 
aggregation under such a high shear rate is called shear-induced platelet aggregation 
(SIPA), which results in an occlusive blood clot formation in under an hour and cessation 




1.2 The Mechanism of SIPA Clot Formation 
It is counter-intuitive as to how SIPA occurs under such pathologic high shear rates of 
400,000 s-1, as this generates a very strong hydrodynamic force that acts on the platelets 
and platelet aggregates. The magnitude of this hydrodynamic force acting on the platelets 
exceeds 10,000 pN (Wellings & Ku, 2012), resulting in harsh flow conditions for the 
formation of SIPA clots. Not only do SIPA clots need to overcome such a severe flow 
conditions, they also need to accumulate billions of platelets to occlude an artery. Histology 
studies have demonstrated that SIPA clots consist of approximately 80% platelets by 
volume (Ku & Flannery, 2007), and billions of platelets must be captured to occlude an 
artery with a diameter > 4 mm (Mehrabadi, Casa, Aidun, & Ku, 2016). These clot-
formation conditions can be achieved via VWF elongation under high shear rates and rapid 
platelet accumulation (RPA) via a positive feedback loop suggested by Casa and Ku 
(2017). 
After the rupture of the plaque cap, the collagen surface is exposed to the blood flow, 
and marginated soluble VWF can bind to fibrillar collagen type 1 or 3 through the A3 
domain, mediated by the A2 domain (Rack et al., 2017; Sakariassen, Houdijk, Sixma, 
Aarts, & de Groot, 1983; Wei et al., 2018). The adsorption of the VWF onto the collagen-
coated surface can be enhanced with higher molecular weight VWF (Santoro, 1981), and 
those shear rates above 5,000 s-1 can unfold the VWF molecule (Schneider et al., 2007). 
The VWF then becomes the dominant molecule that mediates platelet binding for shear 
rates over 1,000 s-1 (Aarts, Steendijk, Sixma, & Heethaar, 1986). The VWF can bind to 
platelets via glycoprotein Ib-A1 (GPIb-A1) without activation or via integrin GPIIb/IIIa-
C1 post-activation (Ruggeri, Orje, Habermann, Federici, & Reininger, 2006). The high 
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shear rate leads to not only to VWF margination but also to platelet margination, where the 
hematocrit and shear rate can increase the platelet concentration near the vessel wall by as 
much as 2.5 folds (Aarts et al., 1988). The marginated platelets can be captured by the 
VWF at the vessel wall, but the high wall shear rate only allows microseconds for the 
platelets to react with the surface (Wellings & Ku, 2012). Based on the platelet activation 
curve given by Hellums (1994), microseconds are not sufficient for platelets to activate. In 
addition, Ruggeri et al. (2006) found that SIPA clots form without platelet activation when 
shear rates exceed 10,000 𝑠!"  and when soluble VWF is present. Thus, it is platelet 
activation-redundant GPIb-A1 binding that is important for the SIPA clot formation under 
pathological high shear rates (Casa & Ku, 2017). 
GPIb is a glycoprotein receptor on the membrane of unactivated platelets that can 
bind to the VWF A1 domain (Ruggeri et al., 2006). A single GPIb-A1 bond has a strength 
of approximately 100 pN; thus, there needs to be more than 1,000 bonds under large 
hydrodynamic forces exceeding 10,000 pN (Tadayuki Yago et al., 2008). Wellings and Ku 
(2012) demonstrated how many bonds and how fast the binding should be, to capture a 
platelet under a high shear rate. To form more than 1,000 bonds, the VWF needs to unfold 
and create a VWF net via self-association to expose the abundant A1 domains. In order to 
generate VWF nets, a localized high VWF concentration is required via 𝛼-granule release 
from activated platelets. 𝛼 -granules have a 50-times higher VWF concentration than 
plasma VWF does (Harrison & Cramer, 1993). Wellings and Ku (2012) concluded that the 
VWF must bind platelets with a kinetic on-rate (kon) ranging from 10# to 10$ M!"s!", 
theoretically. Single VWF molecule studies by Fu et al. (2017) confirmed that the 𝑘%& of 
platelets to VWF A1 is greater than 10' M!"s!", experimentally. 
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After the initial platelet capture, the adhered platelets can be activated to form 
integrin GPIIb/IIIa-C1 bonds for a stable clot formation. Subsequently, these activated 
platelets release molecules such as 𝛼 -granules and dense granules that contain 
procoagulant molecules: ultra-large VWF (ULVWF), fibrinogen, platelet factor 4 (PF4), 
thrombospondin, factor V (FV), factor VIII (FVIII), ADP, ATP, serotonin, and calcium. 
The release of ULVWF creates another reactive surface for more platelet capture on the 
surface. A repeat of this process results in a positive feedback loop for RPA (Figure 1-1) 
that recruits billions of platelets into the stenosis. 
In summary, occlusive thrombus formation under high shear rate conditions can be 
described as a three-phase process of (i) initial platelet attachment to a thrombogenic 
surface (lag phase); (ii) accelerated growth (RPA); and (iii) thrombus stabilization or 
cessation of blood flow (occlusion phase) (Casa & Ku, 2017).  This whole process is 
summarized in Figure 1-1. 
 




1.3 Coagulation Clots and SIPA Clots 
The mechanism for SIPA clot formation is different from the classic Virchow’s triad of 
coagulation-based red clotting (Figure 1-2). Virchow’s triad consists of endothelial 
disruption, stagnant blood flow, and hypercoagulability (Lefkowitz, 2008). In contrast to 
Virchow’s triad, Casa et al. (2015) suggest an alternative triad necessary for arterial 
thrombosis: (i) a collagen surface or other substrate for initial VWF absorption, (ii) a 
pathologically high shear rate for VWF unfolding and elongation, and (iii) platelets and 
VWF in sufficient concentrations (Figure 1-2). 
Due to the distinct formation mechanisms, coagulation clots and SIPA clots are 
composed of different constituents.  The main component of a coagulation clot is fibrin, 
which is a final product of the coagulation cascade that entraps large amounts of Red Blood 
Cells (RBCs). The prevalence of RBCs in coagulation clots is the reason why such clots 
appears to be red, and are often referred to as “red clots.” (Cadroy, Horbett, & Hanson, 
1989). However, a coagulation clot can be white if the clot is formed from artificially 
extracted platelet-rich plasma (PRP) that lacks RBCs but is still fibrin-abundant. On the 
contrary, a SIPA clot consists mostly of platelets and VWFs, as Ku and Flannery (2007) 
found that 80% of SIPA clot consisted of platelets. Due to the relative absence of RBCs 
and the prevalence of platelets, SIPA clots appear to be white and are commonly called 
“white clots.” (Narins & Topol, 1997). 
Another distinctive factor to distinguish between a coagulation clot and a SIPA clot 
is the hemodynamic condition – the shear rate (Figure 1-2). The shear rate in a vessel can 
be defined as the velocity gradient along the vessel’s diameter. Cadroy et al. (1989) showed 
 6 
that SIPA clots form under high shear rates, whereas coagulation clots are created in low-
shear regions. These differences in the hemodynamic conditions for clot formation can be 
used to predict the location of the formation based on the shear rate. Coagulation clots will 
likely form in the low shear regions of venous system or in stagnant regions of medical 
devices (Susan M. Hastings, Deshpande, Wagoner, Maher, & Ku, 2016), whereas SIPA 
clots form in the arterial system or in high-shear regions of medical devices. 
 
 
Figure 1-2. Essential triads for coagulation and SIPA clot formation. 
 
1.4 Treatments for Arterial Thrombosis 
The main goal of arterial thrombosis treatment is to regain the blood flow by removing the 
occlusive thrombus. Currently, there are two types of treatments available in the clinical 
field: thrombolytic therapy and a thrombectomy. Thrombolytic therapy is a chemical 
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method for removing the thrombus by administrating a lysis agent, for instance, 
intravenous (IV) tissue Plasminogen Activator (tPA). On the other hand, a thrombectomy 
utilizes mechanical forces to retrieve the thrombus from an artery (Figure 1-3). 
tPA is the only Food and Drug Administration (FDA) approved thrombolytic agent 
in the United States (Chapman et al., 2014). Astrup and Permin (1947) first discovered 
tPA, and it was tested with different types of in vitro assays: a  fibrin plate (Astrup & 
Müllertz, 1952) and a circulating plasma system (Matsuo, Rijken, & Collen, 1981a). 
Success in the in vitro assays led to multiple in vivo studies (Matsuo, Rijken, & Collen, 
1981b), a small clinical study (Bergmann, Fox, Ter-Pogossian, Sobel, & Collen, 1983), 
and large clinical trials (Collen et al., 1984; The GUSTO Angiographic Investigators, 1993; 
The GUSTO Investigators, 1993). However, patients must receive treatment within a 
small-time window of 3 hours from the onset of symptoms, and many individuals have 
contraindications, such as a recent surgery or bleeding (Bivard, Lin, & Parsonsb, 2013; 
Prabhakaran, Ruff, & Bernstein, 2015). tPA has been shown to have a limited 
recanalization rate of less than 30% (Bhatia et al., 2010). In addition, a 30% relative risk 
reduction was found versus the placebo in stroke patients who had tPA administrated, but 
ultimately, there was no statistically significant improvement in the overall mortality rate 
with the use of tPA (Chapman et al., 2014). tPA induces the conversion of plasminogen to 
its active form, plasmin, in the vicinity of a hemostatic plug. Plasmin then cleaves fibrin, 
thus lysing the thrombus (Bivard et al., 2013; Brenner, 1988). However, thrombi that cause 
an arterial occlusion are not fibrin-rich, and thus tPA may not be effective in this 
environment. SIPA clots in arteries are structurally very different from a fibrin gel (Ku & 
Flannery, 2007). 
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In order to undertake a thrombectomy, the occlusion site needs to be located first and 
then a clinician can use a catheter to reach the thrombi. There are many thrombectomy 
devices on the market, but mainly, there are two types: wire-based devices and aspiration 
devices (Raychev & Saver, 2012). Wire-based devices (e.g., a coil retriever and stent 
retriever) poke or wrap the thrombi and then retrieve it into the catheter using frictional 
force. Meanwhile, aspiration thrombectomy devices use suction force to break and retrieve 
thrombi. Saver et al. (2015) found in their clinical study (39 centers and 196 patients) that 
a patient group who had stent retriever with tPA showed 88% recanalization rate and rate 
of functional independence at 90 days was higher compared to a group who had only tPA 
(60% vs. 30%, p < 0.001). Flynn et al. (2017) did a meta-analysis of eight thrombectomy 
clinical trials (1,841 patients) and found no significant effect on mortality at 90 days or 
symptomatic intracranial hemorrhage. 
 
Figure 1-3. (A) Thrombolytic therapy using tPA. (B) thrombectomy device retrieving 
a blood clot. 
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CHAPTER 2. CRITICAL ROLE OF a-GRANULES FOR 
ARTERIAL THROMBOSIS  
2.1 Introduction 
Mehrabadi et al. (2016) have identified three phases for the SIPA process: (i) a lag phase 
with limited platelet attachments to the thrombogenic surface, (ii) RPA via explosive 
platelet aggregation, and (iii) post-occlusion that involves clot stabilization or 
embolization. During the RPA phase, billions of platelets must be captured onto the 
thrombogenic surface while traveling through the stenosis in microseconds and under a 
high hydrodynamic force of over 10,000 pN. Wellings and Ku (2012) used a theoretical 
analysis to predict that a fast-moving platelet can only be captured only if the VWFs are of 
sufficient concentration to form many multiple bonds as concave nets and where the kon is 
greater than 108 M-1s-1. This analysis suggests that the plasma VWF concentration would 
be insufficient to capture the large number of platelets needed for RPA. Thus, a source of 
local VWF would be necessary for RPA and the subsequent occlusive thrombosis.   
Such a local source might be the α-granules in platelets, as they contain ULVWF 
(Fernandez, Ginsberg, Ruggeri, Batlle, & Zimmerman, 1982; Moake, Turner, 
Stathopoulos, Nolasco, & Hellums, 1988). The α-granule is composed of secretory vesicles 
inside platelets that contains VWF, thrombospondin, fibronectin, and FV (Whiteheart, 
2011). The VWF is the dominant protein that mediates platelet aggregation and thrombosis 
under pathologically high shear rates (Kim, Bresette, Liu, & Ku, 2019). Coagulation factors 
are prone to being transported away from the stenosis before the coagulation cascade is 
completed. However, there are studies showing fibronectin can play a role in platelet 
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aggregation and thrombus growth under high shear rates (S. P. Jackson, 2007). However, 
fibronectin concentration in a-granules (0.19 mg/mL) is smaller than the plasma 
concentration is (0.30 mg/mL) (Harrison & Martin Cramer, 1993), which, in turn, implies 
a lesser effect is expected on thrombosis in the absence of a-granules. The VWF  inside 
the α-granule has a 50-fold higher concentration than plasma VWF does (Harrison & 
Martin Cramer, 1993) and is capable of mediating platelet aggregation under high shear 
rates of 120 dyne/cm2 (Moake et al., 1988). Platelets release the contents of their α-granules 
upon activation, which may be stimulated by the high-shear stress or by thrombin. The α-
granule may be necessary for RPA, and thus may be a target via which to prevent 
subsequent occlusive thrombosis. While Wellings and Ku (2012) hypothesized the 
criticality of the α-granule VWF, to best of the author’s knowledge, this has not yet been 
tested experimentally. 
The neurobeachin-like 2 gene (Nbeal2)-deficient mouse has been linked to the Gray 
Platelet Syndrome (GPS) (Albers et al., 2011; Deppermann, Nurden, Nurden, Nieswandt, 
& Stegner, 2013), which is a rare autosomal-recessive platelet disorder characterized by 
thrombocytopenia, large gray platelets lacking α-granules, and moderate bleeding. The 
Nbeal2 knock-out (Nbeal2-/-) mouse lacks the α-granule VWF but has a normal plasma 
VWF level compared to the wild type (WT) (Deppermann, Cherpokova, et al., 2013; Kahr 
et al., 2013). This difference is exploited in the Nbeal2-/- murine model to study the 
importance of α-granules on the high-shear thrombosis. Kahr et al. (2013) studied the 
platelet function of Nbeal2-/- and found less platelet aggregation compared to the WT in in 
vitro assays with a defect in thrombus formation using a laser-injury cremaster arteriole 
model. However, they only monitored the blood flow in the arteriole for a limited time of 
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3 min and no occlusion was found in the vessel. Deppermann, Cherpokova, et al. (2013) 
showed a similar defect in platelet aggregation and thrombus formation in Nbeal2-/-. They 
used two different in vivo arterial thrombosis models: a ferric-chloride injury mesenteric 
arteriole model and a mechanically injured abdominal aorta murine model. Unstable or no 
occlusive thrombosis was found in Nbeal2-/- mice, whereas the WT showed full occlusion. 
Neither study took into account pathologically high shear rates, and they only tested under 
physiological arterial shear conditions (1,700 s-1 at maximum), which would not force the 
need for α-granule VWFs. 
This study aims to investigate the effect of α-granule VWF presence on the 
occlusive thrombosis by creating pathological high-shear conditions and using Nbeal2-/- 
mice. First, we predict the occlusion time with normal whole blood (WB); with platelets 
with no α-granules (Nbeal2-/- platelets); and then we test a rescue situation where normal 
platelets are perfused after Nbeal2-/- platelets are. Experimental thrombotic occlusion is 
tested in a stenotic microfluidic system, that is optimized for the small blood volumes from 
mice where rescue is possible. Lastly, we test for occlusion in mice by suturing the carotid 
artery until the flow rate reaches 50% of the baseline. The resulting in vivo thrombosis was 
measured by flow rate and histological analysis. The study then compares the in vitro and 
in vivo quantitative data against the in silico predictions as a rigorous test of our 






2.2.1 Computational Fluid Dynamics analysis 
Computational fluid dynamics (CFD) were used to predict the shear-rate distribution within 
a microfluidic geometry and a mice carotid artery geometry. Simulations were performed 
using Ansys 19.1 (Ansys Inc, PA, USA). Whole blood flow was assumed to be Newtonian 
fluid of 3.5 cP, and the flow was presumed to be laminar, incompressible, steady, on a 
continuum, and isothermal due to the low Reynolds number in the experiments.  The 
microfluidic chamber was modeled as a rectangular channel with a total pressure inlet of 
4.8 mmHg and a uniform zero pressure (gage) outlet. The no-slip boundary condition was 
applied to the walls (Figure 2-3A). A stenosed mouse carotid artery had inner diameter 
(ID) of 0.45 mm and was modeled as a 60%-diameter constriction of a cylindrical vessel 
and a 0.25 mL/min flow rate was applied at the inlet with a zero pressure at the outlet 
(Figure 2-3B). Mesh convergence was achieved at 3.5 million and 4 million tetrahedral 
cells, yielding a residual error of 10-9 for each model, respectively. 
2.2.2 Arterial thrombosis model for simulating the occlusion time 
Time to occlusion in a stenotic microfluidic test section or mouse carotid artery was  
predicted using the quantitative, empirical, high-shear thrombosis model by Mehrabadi et 
al. (2016). The model is composed of a lag phase and RPA phase that are defined by: 
 𝑡()* = 1.69	 ×	10'𝑆!"., (1) 
where tLag is the lag time and S is the wall shear rate. The thrombus growth rate during the 
RPA phase is expressed by the time and shear rate (S). 
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𝐽 = 	 W
0																					, 𝑡 ≤ 𝑡()*	
𝑎𝑒-. + 𝑐𝑒/., 𝑡 > 𝑡()*	
 (2) 
The constants a, b, c, and d are given in Table 1. The lower and upper confidence 
limits of thrombus growth are denoted by JMIN and JMAX respectively. 
Table 1. Constants for the RPA phase thrombus growth-rate equation. 
 a b (x10-4) c d (x10-6) 
JMIN -28.3 -1.00 27.4 -10.0 
JAVG -31.3 -1.45 30.7 -6.81 
JMAX -38.2 -1.81 36.6 -5.92 
Our high-shear microfluidic device was modeled as a straight rectangular channel. 





The constants Q, w, and h are the flow rate, channel width, and channel height 
respectively. The geometry values are specified in Figure 2-3. 
To model the stenosis of the mouse carotid artery, a 60%-diameter stenosis was 
applied to a cylindrical channel to cause an approximately 50% reduction in flow rate (Bark 
Jr & Ku, 2010). The assumptions of Poiseuille flow were applied at the throat, and the 






where the constants Q, w, and h are the flow rate, channel width, and channel height, 
respectively, and D denotes the channel diameter.  
The channel height/diameter was updated every second as thrombus growth 
increased in both models. 
2.2.3 Mice 
Nbeal2-/- and WT control mice were generated from Nbeal2+/- mice on a C57/bl6 
background (Deppermann, Nurden, et al., 2013) with a targeted deletion region between 
exons 4-11 of Nbeal2 (B6;129S5-Nbeal2tm1Lex/Mmucd) (Kahr et al., 2013). Equal 
numbers of 12~20-week-old male and female mice were used. All animal experiments 
were approved by the university animal care and use committees. 
2.2.4 High-shear microfluidic stenosis model 
Polydimethylsiloxane (PDMS) microchannels with a stenotic region were used for in vitro 
studies of WB occlusion at the pathological shear rate (Casa, Gillespie, Meeks, & Ku, 
2016). Approximately 1~2 mL of blood can be drawn from mouse; thus, microfluidic set-
up was optimized to use minimal blood for each run. Previous set-up required 6 mL of 
blood for each run, but by removing tubes and directly connecting reservoir to the inlet, 
necessary blood volume is reduced to 1.5 mL for the current set-up (Figure 2-1). WB was 
collected from the inferior vena cava (IVC) of the Nbeal2-/- and WT mice into heparin 
anticoagulant (15 USP/mL), and the platelets were fluorescently labeled with DIOC6 
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(Invitrogen, CA, USA). WB was perfused through the microfluidic device at a constant 
upstream pressure head of 65 mmHg on immobilized type-1 fibrillar collagen (Chronolog, 
PA, USA). Platelet adhesion and occlusion were captured in real time with an ORCA 
Flash4 CMOS camera (Orca‐ER, Hamamatsu, Japan) and CellSens software (Olympus, 
PA, USA) with images being acquired every 1 s for the duration of the experiment. The 
occlusion time was defined for each series when the centerline RBC velocities decreased 
to less than 100 µm/s. 
 
Figure 2-1. Microfluidic set-up (A) before and (B) after the optimization for the 
minimal blood usage. 
 
Figure 2-2. (A) Microfluidic set-up optimization using porcine blood before mice 
blood test. (B) Top-down view of blood flow in microfluidic channel. (C) Platelet 
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adhesion, (D) SIPA clot formation, and (E) occlusion was achieved with 1.5 mL of 
blood. 
2.2.5 Folts-like arterial stenosis model 
In vivo thrombus formation under the pathological shear rate was assessed using the Folts-
like model of arterial thrombosis (Sturgeon, Jones, Angus, & Wright, 2006). A 6.0 silk 
suture was tied around the common carotid artery until the blood flow rate was reduced to 
approximately 50%, as monitored using a flow probe (Transonic Systems, NY, USA) to 
create a stenosis region and a high shear-stress environment. The carotid vessel under the 
stenosis was gently crushed using forceps to expose the subendothelial surface, and the 
blood flow was continuously monitored. Blood flow data were acquired with Powerlab, 
and analyzed using LabChart Pro version 8.1 (ADInstruments, CO, USA). Occlusive 
thrombus formation occurred when blood flow decreased to zero. Following experiments, 
the carotid artery, including the injury site, was dissected and fixed in neutral buffered 
formalin fixative overnight. The tissue was embedded in paraffin, sectioned, and stained 
using either hematoxylin and eosin (H&E) or the Carstairs method (Electron Microscopy 
Sciences. PA, USA). The histology images were captured using an Olympus BX42 
microscope and Olympus DP72 digital camera with CellSens software (Olympus, PA, 
USA). The thrombus structure and composition were assessed where the platelets stained 
blue/purple, fibrin stained red, RBCs stained yellow, and the collagen was blue. A detailed 
protocol is described in Appendix A. 
2.2.6 Analysis 
The image analysis was performed using FIJI/ ImageJ 1.51n (NIH, USA), and the data 
were processed with Matlab (Mathworks, Natick, MA). The data analysis was performed 
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using GraphPad Prism 7 (GraphPad Software, San Diego, CA). Statistical significance (p 
< 0.05) was determined using the unpaired t-test or by one-way ANOVAs with Dunnett’s 
post-tests for multiple comparisons (Upton & Cook, 2006). Data are displayed as mean 
with error bars denoting standard error of the mean (SEOM). 
2.3 Results 
2.3.1 Hemodynamic flow through a high shear microfluidic device and stenosed mouse 
carotid artery 
We produced a microfluidic channel that mimics the stenosis of arteries. This system 
allows for the direct visualization of thrombus growth all the way to flow occlusion. We 
used the microfluidic channel geometry (Figure 2-3A) from Casa and Ku (2014) to 
incorporate not just platelet adhesion, but also RPA and the subsequent a massive levels of 
platelet aggregation. The maximum initial shear rate that occurred in the stenotic region of 
the channel was > 3,600 s-1, whereas the upstream and downstream regions remained at a 
shear rate of < 1,000 s-1 (Figure 2-3C), comparable to the physiological arterial wall shear 
rate. The occlusion time for each channel was predicted using a quantitative, empirical 
high-shear thrombosis model described by Mehrabadi et al. (2016). A constant flow rate 
was assumed, and the occlusion time was defined as the point where the pressure difference 
reached the mean arterial pressure of a mouse (100 mmHg) and reached a constant pressure 
head at the inlet (4.8 mmHg) in the microfluidic set-up. The microfluidic channel occlusion 
time was predicted to be 264 ± 65 s, including a lag time of 109 s. The simulated thrombus 
growth and the shear rate build up during high-shear thrombosis formation in each channel 
is depicted in Figure 2-3E and F. The shear rate was expected to increase to as much as 
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100,000 s-1 and 10,000 s-1, respectively. The mouse carotid artery dimensions were used 
for separate predictions for the in vivo situation. Based on previous studies (Bark Jr & Ku, 
2010), a 60%-diameter stenosis in diameter causes an approximately 50% flow-rate 
reduction. Thus, the carotid stenosed artery is modeled as shown in Figure 2-3D, as a 60% 
stenosis with axisymmetric geometry. The shear-rate contour is described in Figure 2-3D, 
showing a maximum shear rate of 4,600 s-1 at the apex of the stenosis. No flow separation 
was seen in the distal area to the stenosis for this mouse artery stenosis. The occlusion time 
for the mouse was predicted to be 305 ± 77 s with a lag time of 81 s. 
 
Figure 2-3. Hydrodynamic flow characteristics through a high-shear microfluidic 
device and stenosed mouse carotid artery. (A) Geometry of the microfluidic model 
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with a stenotic test section. (B) Schematic of in vivo experiments showing a stenotic 
region relative to flow direction and flow-probe placement. (C) CFD simulations of 
the microfluidic device. Blood flows from left to right. The color contour shows the 
shear strain-rate distribution. The solution shows a maximum shear strain rate of > 
3,500 s-1 in the stenosis region, while the upstream and downstream values are < 1,000 
s-1. (D) CFD simulation in a stenosed mouse carotid artery. The large velocity gradient 
at the stenotic apex leads to initial shear rates that exceed 4,000 s-1. (E) & (F) 
Thrombus growth was predicted using a high-shear thrombosis model by Mehrabadi 
et al. (2016). The shear strain-rate estimation over time during high-shear thrombosis 
formation in a microfluidic assay and mouse carotid artery. Min and Max denote for 
the lower and upper confidence limits of the model. 
 
2.3.2 Platelet VWF is necessary to form occlusive thrombi 
To visualize and conduct a rescue study, we perfused mice blood into the high-shear 
microfluidic channels. Prior to the mice study, the microfluidic set-up was optimized using 
porcine blood to reduce the required volume by removing extra tubing and connecting the 
reservoir directly to the microfluidic channel inlet. As a result, the single perfusion only 
takes 1.5-2 mL of blood, which is a 3~4 times reduction compared to the previous set-up. 
We obtained 1-1.5 mL of blood from each mouse and combined blood from two mice for 
each run. A constant pressure head of 4.8 mmHg was applied at the inlet, and the stenotic 
region of the channel was visualized by microscope. To enhance the visualization, we 
labeled the platelets with fluorescent dye. All seven WT mice blood experiments formed 
RPA and went to occlusion in 326 ± 25 s. In contrast, Nbeal2-/- mice blood showed only 
small amounts of platelet adhesion on the surface and no occlusion after 8 min (Figure 
2-4). We then attempted to rescue the non-occluded channels by perfusing them with the 
WT mice blood. The rescued channels then formed RPA and went to occlusion in 166 ± 
48 s (Figure 2-4B).  
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All the images were post-processed to compare the intensity levels in the test 
sections. Figure 2-4C describes the normalized intensity of the WT, Nbeal2-/-, and rescue 
(WT) mice blood. The intensity of the WT mice blood increased rapidly, but the intensity 
of the Nbeal2-/- blood became saturated at 20%. The intensity in the Nbeal2-/- channels 
again increased rapidly post-rescue. The occlusion times for the WT, Nbeal2-/-, and rescue 
blood were significantly different (Figure 2-4D, p < 0.05).  
 
Figure 2-4. Plasma VWF is sufficient for the initial adhesion of platelets to collagen, 
while locally released platelet VWF is necessary for forming the subsequent occlusive 
thrombi. Representations of WT and Nbeal2-/- platelet adhesion and the subsequent 
occlusion during the 8-min perfusion period. The progressive accumulation of 
platelets is observed over time. (A) WT mice blood showed rapid and significant 
platelet adhesion and aggregation leading to occlusion. (B) Nbeal2-/- mice blood did 
not form occlusive thrombi during the 8-min observation period. Occlusive thrombi 
formed following the addition of WT whole blood (Rescue) to adherent Nbeal2-/- 
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platelets on collagen. The 1-mm stenosis region is marked with a red line under the 
image. The region of interest (ROI) appears blank before the adhesion of platelets 
(green, DIOC6). The flow direction is from left to right. Scale bar, 1,000 µm. (C) 
Normalized fluorescent intensities comparing thrombus growth and occlusion in the 
control WT (n = 6), Nbeal2-/- (n = 6), and Rescue (n = 3) channels. The initial lag phase 
is quickly proceeded by RPA, demonstrated by a fast increase in thrombus size and 
intensity at approximately 100 seconds for WT whole blood and at 515 ± 47 s for 
Nbeal2-/- + WT whole blood. Occlusion occurs at the end of the plot for WT and 
Nbeal2-/- + WT whole blood. No occlusion was observed with Nbeal2-/- whole blood 
alone. A black arrow denotes the time point when WT whole blood was added to the 
Nbeal2-/- channels. All images were post-processed and averaged to compare the 
intensity levels in the test sections. (D) Occlusion times in the microfluidic device for 
WT (326 ± 25 s), Nbeal2-/- (no occlusion), and Nbeal2-/- + WT (166 ± 48 s) blood. All 
three occlusion times are significantly different from each other (p < 0.001). 
2.3.3 Platelet VWF release induces localized formation of an occlusive thrombi 
After platelet activation, a high concentration of ULVWF can be released from the 
activated platelets. A localized release of VWF could provoke the localized formation of 
occlusive thrombi. With identical microfluid channels and flow conditions, Griffin, Kim, 
and Ku (2019) found that a localized thrombus formed with human blood (Figure 2-5). To 
investigate whether the same outcome would occur for the mouse blood, we split the region 
of interest (ROI) into three ROIs (Figure 2-6A) and compared the intensity level of each 
ROI. The final intensity level in the ROI 1 (upstream) was significantly higher than the 
other 2 ROIs for the WT and Rescue (Figure 2-6B, p < 0.01), but there was no significant 
difference between the ROIs for Nbeal2-/-. The intensity level of each ROI over perfusion 
time (Figure 2-6C & D) showed a sudden intensity increase in ROI 1 for the WT (80 s) and 
Rescue (20 s), but only a small intensity level increase in ROI 2 and 3. Thus, RPA occurs 
in the confined upstream part of the stenosis (333 µm), and serves as the dominant location 
for the channel occlusion in the microfluidic system. 
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Figure 2-5. Human SIPA clots forms at upstream regions of stenotic section in 
microfluidics (n = 8). (A) Channel is separated into 5 ROIs. (B) ROI 1 showed 
significantly higher normalized intensity level compare to the other ROIs (p < 0.0001). 
ROI 2 and 3 had a 50% lower intensity level compare to ROI 1. ROI 0 and 4 had 
lowest intensity level approximately 10% lower than ROI 1. 
 
Figure 2-6. The platelet VWF induces the localized formation of occlusive thrombi. 
(A) The three ROIs for the microfluidic channel test section. (B) Normalized 
fluorescent intensity level of each ROI after an 8-min perfusion for WT (n = 6) and 
Nbeal2-/- (n = 3), and a 5-min perfusion for the Rescue (n = 3). ROI 1 showed a 
significantly higher intensity level with WT (p < 0.001) and Rescue (p < 0.01) 
compared to ROI 2 and 3. There was no significant increase in ROI 1 with Nbeal2-/-. 
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(C) & (D) Intensity levels of each ROI over perfusion time. The black arrow denotes 
the time point when WT whole blood was added to the Nbeal2-/- channels. The 
intensity level of ROI 1 rapidly increased after 80 s for the WT and 20 s for the Rescue. 
 
2.3.4 Occlusive thrombus did not form in the Folts-like arterial stenosis model without 
platelet von Willebrand Factor (Nbeal2-/-) 
Using the Folts-like murine model, the distal flow rate was monitored before and after the 
crush injury, as shown in Figure 2-7A. After suturing the carotid artery to generate the 
stenosis, we waited for more than 2 min for the flow rate to stabilize. All flow rates for the 
WT mice eventually decreased to 0 mL/min. In contrast, none of the Nbeal2-/- mice showed 
flow cessation (p < 0.0005). The occlusion time in WT mice was 352 s on average 
following de-endothelization of the stenosed vessel. This is comparable to the predicted 
occlusion time of 305 ± 77 s. We then collected carotid arteries from the thrombosed mice 
to perform histology to identify clots and their composition. Figure 2-7C & D shows the 
platelet-rich thrombus in the WT artery, but no thrombus was observed in the Nbeal2-/- 
mice. These findings support platelet VWF from α-granules being critical for occlusive 
thrombus formation in a stenosed arteries. 
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Figure 2-7. The absence of platelet VWF prevents occlusive thrombus formation in 
the modified Folts arterial stenosis model. (A) Mean blood flow through the carotid 
artery with an ~50 % stenosis (reduction in blood flow) and crush injury. WT mice 
consistently formed an occlusive thrombus in response to the stenosis and a crush 
injury. In contrast, there was no occlusive thrombus formation in the carotid artery 
of the Nbeal2-/- mice (n = 7 ± SEOM, p < 0.0001). (B) WT mice formed occlusive 
thrombi at an average time of 330 sec following de-endothelization of the stenosed 
vessel. Nbeal2-/- mice were unable to form occlusive thrombi in vivo. (n = 7 ± SEOM, 
p < 0.0005). (C) Representative macroscopic images of the gross anatomy of an excised 
carotid artery from WT and Nbeal2-/- mice. The WT carotid artery features a 
prominent clot (arrowheads) within the longitudinal arterial lumen (outlined), 
suggesting the presence of an occlusion.  There is a clear absence of occlusive matter 
within the lumen of the Nbeal2-/- carotid artery (outlined). (D) Carstairs histological 
staining revealed that WT thrombi were primarily composed of platelets (the blue 
material occluding in the lumen). 
 
2.3.5 Platelet von Willebrand Factor is essential for the rapid platelet accumulation 
phase and induces vessel occlusion 
We applied the thrombosis growth model by Mehrabadi et al. (2016) for microfluidics and 
the mouse carotid artery, and compared occlusion times with the experimental results. The 
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microfluidic channel was predicted to have a lag phase time of 138 s, followed by RPA 
phase of 109 s, resulting in a total occlusion time of 247 s, which is comparable to the 
experimental result (326 ± 25 s). Nbeal2-/- mice did not advance from the lag phase, and no 
RPA was observed. However, when WT mouse platelets were perfused through to the same 
device channel containing Nbeal2-/- adherent platelets, the RPA phase occurred almost 
immediately. The Nbeal2-/- lag time was subtracted from the RPA phase time of the rescue 
(WT), and the experimental results with an occlusion time of 170 ± 57 s were comparable 
to the predicted values for RPA occlusion of 138 s (Figure 2-8). 
In simulations of a 60%-diameter stenosed mouse carotid artery, the modeled 
occlusion time was calculated as 305 s, which was similar to the WT in vivo experiments 
that exhibited a mean occlusion time of 352 s (Figure 2-8). 
 
Figure 2-8. Comparison of simulated occlusion times against actual experimental 





We used the two-phase arterial thrombosis model by Mehrabadi et al. (2016), to predict 
occlusion times and the shear rate during high-shear thrombosis formation. The model is 
simplified by assuming a constant flow rate and used pressure as the end point to predict 
occlusion time. The simulated occlusion times were in good agreement with what was we 
found in the experiments, and we were able to predict the rescue time by subtracting the 
simulated lag time. Para and Ku (2013) demonstrated experimentally that the occlusion 
time is equivalent when they used the same end point as we used in this model. 
α-granules are necessary for the initiation of the RPA phase, and the Nbeal2-/- mice 
did not show RPA and occlusion in either the in vitro or in vivo models. To confirm the 
result, we rescued Nbeal2-/- mice with WT mice blood by perfusing into the same 
microfluidic channel. We found that there was restoration of large platelet aggregation and 
RPA, and the occlusion time was significantly faster than for the WT mice blood alone. 
The plasma VWF levels do allow for the adhesion of some fast-moving platelets to 
complete the lag phase of surface coverage. However, to reach RPA with the capture of 
10x as many platelets at the wall, the α-granules are necessary. The Nbeal2-/- murine model 
verifies in vivo the critical role of α-granules for occlusive, high-shear thrombosis. α-
granules store high concentrations of ULVWF, the most important protein for the high-
shear thrombosis. An occlusive thrombus is only formed in the presence of platelets with 
normal α-granules. This was seen when collected carotid artery was performed histology.  
Nbeal2-/- mice blood has previously been reported to have normal plasma VWF, 
but a 40% lower platelet counts compared to the WT (Deppermann, Cherpokova, et al., 
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2013; Kahr et al., 2013). However, Casa et al. (2016) showed 10% platelet-diluted blood 
can still form a high-shear thrombosis but not with plasma VWF at a 10% dilution. We 
found that all of the WT mice carotid arteries went to occlusion, but no occlusion was 
observed for the Nbeal2-/- mice. In the WT vessel, we found platelet-rich thrombi occluding 
the lumen. Similar results were seen in the microfluidic study, and we found that there was 
a large aggregation and occlusion with WT mice blood. Nbeal2-/- mice blood only showed 
adhesion on the surface but no RPA or occlusion. 
Previous Nbeal2-/- mice thrombus formation studies by Kahr et al. (2013) and 
Deppermann, Cherpokova, et al. (2013) only accounted for maximum physiological 
arterial shear  rates of 1,700 s-1 at and not for pathological shear rates over 3,000 s-1 and up 
to 100,000 s-1. Under physiological shear rate, the role of α-granule VWFs on thrombus 
formation could be subsidiary and not important for the vessel occlusion. Except for the 
abdominal aorta model by Deppermann, Cherpokova, et al. (2013), both groups used small 
arterioles that could be prone to occlude with only platelet adhesion during the lag phase 
and not with RPA. Casa and Ku (2014) suggest that circular channels should be no more 
than 90 µm in diameter, with a rectangular channel height greater than 50 µm, and with a 
high aspect ratio to take into account platelet-platelet interaction, which is critical for the 
RPA phase. In this study, we created a stenotic microfluidic channel and sutured mice 
carotid artery that satisfied both criteria (high shear rate and a large enough channel) and 
that can incorporate not only the lag phase, but also the RPA phase. 
The VWF is the most important protein that regulates high-shear thrombosis. It 
originates from endothelial cell-derived plasma VWFs and platelet α-granule-released 
VWFs. The other α-granule proteins, fibronectin and thrombospondin may help a SIPA 
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clot to stabilize but are likely not as important as VWF for the SIPA clot to grow under 
high shear conditions as they are short and in lower concentration. Ruggeri et al. (2006) 
emphasized the dominant role of plasma VWFs under high shear conditions on large 
platelet aggregation. They found that an absence of plasma VWFs suppressed platelet 
aggregation under a 1,500 s-1 shear rate but had no impact under 500 s-1. However, platelet 
VWFs could be more, or at least equivalently important for the high-shear thrombosis and 
vessel occlusion. Even with the normal plasma VWFs, the Nbeal2-/- mice showed no 
occlusion in vitro and in vivo, and they were limited to platelet adhesion or small platelet 
aggregation at the wall. Thus, plasma VWFs could be important for the lag phase but not 
for the RPA phase, and platelet VWFs are more important for the RPA phase. 
Current antithrombotic therapies, such as aspirin (ASA) and Plavix® (Clopidogrel) 
target different pathways of platelet activation in general. However, inhibiting platelet 
activation may enhance antithrombotic effects but it can also cause severe bleeding 
complications (Mauri et al., 2014). On the other hand, hemostasis may not require platelet 
VWFs, and targeting α-granules or α-granule released VWFs could be a potential novel 
antithrombotic therapy. Indeed, GPS patients have a mild to moderate bleeding tendency 
(Gunay-Aygun et al., 2010; Jantunen, Hänninen, Naukkarinen, Vornanen, & Lahtinen, 
1994; Nurden & Nurden, 2007), yet even this bleeding could be improved by specifically 
targeting platelet VWFs while preserving the other α-granule proteins, thrombospondin, 
fibronectin, and FV. 
This study has two main limitations. One limitation is that the animals we used were 
mice and porcine for the in vitro set-up optimization. We could have used GPS patient’ 
blood for the same rescue experiments that we performed with Nbeal2-/- mice blood. The 
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second limitation is that although we emphasized the importance of the platelet VWF, we 
have not proved experimentally that platelet VWFs are important for the high-shear 
thrombosis and vessel occlusion; rather, this is limited to the α-granule. These topics are 
for the future study. 
2.5 Conclusion 
The critical role of platelet VWF release on the formation of an occlusive thrombus is 
demonstrated. A combination of in silico predictions with in vitro and in vivo experiments 
revealed the necessary role of α-granules for RPA phase initiation and SIPA thrombus 
formation. The essential part of platelet VWF to induce SIPA under high-shear conditions 
in stenotic arteries makes it a potential new target for pharmacological interventions to 
prevent SIPA clot formation in myocardial infarction or stroke patients. 
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CHAPTER 3. THE PERMEABILITY AND MECHANICAL 
STRENGTH OF A SIPA CLOT 
3.1 Introduction 
Arterial thrombosis in a coronary artery or carotid artery can lead to a myocardial 
infarction or an acute ischemic stroke. The formation of an occlusive thrombus in these 
arteries blocks blood flow and impinges heart or brain function, resulting in the patient’s 
death. To cease the blood flow, the thrombus needs to resist a high shear rate up to 400,000 
s-1 (Bark & Ku, 2010) and arterial blood pressure over 175 mmHg (Stamler, Neaton, & 
Wentworth, 1989). Currently, the available treatments for arterial thrombosis are 
thrombolytic drugs or a thrombectomy. 
 A thrombolytic agent such as tPA hopefully chemically dissolves clots to regain 
blood flow in the vessel. It is critical to systemically administer the tPA within three hours 
of symptom onset to achieve a significant clinical outcome (Bivard et al., 2013). To initiate 
the chemical reaction, the drug needs to be delivered to the clot. Considering a blood clot 
as a porous material, its permeability is strongly related to the delivery of the thrombolytic 
drug via convection and diffusion (Diamond, 1999; Piebalgs et al., 2018). In a clinical trial, 
Santos Emilie et al. (2016) found that patients had 3.2 times more favourable outcomes 
and 2.5 times higher recanalization rates when the clot was more permeable. Wufsus, 
Macera, and Neeves (2013) measured platelet-rich clot permeability under static 
conditions, finding that the coagulation clot permeability ranges from 1.1 x 10-2 µm2 to 1.5 
x 10-5 µm2. Meanwhile, Kobayashi, Sekar, and Ku (2016) observed erythrocytes traveling 
through an occlusive SIPA clot with a distal velocity of 100 µm/s. Thus, SIPA clots might 
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have significantly high permeability compared to coagulation clots. However, no previous 
studies have measured the permeability of SIPA clots that are formed under pathological 
high shear rates. The permeability of the clot is also important for aspirational 
thrombectomy devices that use fluid force for the clot breakage and retrieval. Mokin et al. 
(2020) found that clot perviousness was associated with the first pass success of aspiration 
thrombectomy in a clinical trial. They also found that perviousness had no significant 
correlation with the stent retriever thrombectomy group. 
 Stent or coil retrievers are wire-based thrombectomy devices that apply mechanical 
force to break and retrieve a clot. Thus, the mechanical strength of the clot could be more 
important that permeability for the success of mechanical thrombectomy devices. While 
breaking and retrieving a clot, it becomes deformed, elongated, thinned, fractured, and 
fragmented (Yang et al., 2020). Yeo et al. (2019) suggested that successful thrombectomy 
depends on clot composition and properties, such as friction (Gunning et al., 2018), 
maturity (Duffy et al., 2017), and stickiness (Pikija et al., 2016). Clinically, 
Thromboelastography (TEG) has been used to measure clot strength and predict clinical 
outcome of ischemic stroke (Yao et al., 2014) and coronary artery disease patients (Bitar 
& Kreutz, 2013). However, TEG indirectly measures clot strength using the 
unphysiological swirling motion of a rod in a clot to measure resisting force. Many studies 
have attempted to measure the mechanical strength of a blood clot using various methods, 
including the tensile tester, the compression tester, a dynamic mechanical analyzer, a 
rheometer, dynamic ultrasound viscoelastography, nanoindentation, and a viscometer 
(Johnson et al., 2017). However, these measurements only examined coagulation clots and 
resulted in very distinctive values at 10 orders of magnitude (Figure 3-1). The tested 
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coagulation clots were either collected (Intraluminal thrombus from abdominal aortic 
aneurism: Di Martino et al. (1998), Gasser, Görgülü, Folkesson, and Swedenborg (2008), 
Teng et al. (2015), and Ashton, Vande Geest, Simon, and Haskett (2009) / Deep vein 
thrombus: Xie et al. (2005)) or generated via in vitro assays (Chueh et al. (2011), van Dam 
et al. (2006), Schmitt, Hadj Henni, and Cloutier (2011), Slaboch, Alber, Rosen, and Ovaert 
(2012), Henderson and Thurston (1993), McCarty et al. (2011), Riha, Wang, Liao, and 
Stoltz (1999), Ryan, Mockros, Weisel, and Lorand (1999), and Hinnen, Rixen, Koning, 
van Bockel, and Hamming (2007)).  
Coagulation clots and SIPA clots differ in terms of their formation mechanism and 
composition. A coagulation clot follows the classic Virchow’s triad (Figure 1-2), which 
consists of endothelial disruption, stagnant blood flow, and hypercoagulability (Lefkowitz, 
2008). The main component of a coagulation clot is fibrin, which is the final product of the 
coagulation cascade that entraps large amounts of RBCs. A coagulation clot is often 
referred to as a red clot because it appears to be red in color due to the presence of a large 
number of RBCs. However, a coagulation clot can appear to be white in color if the clot is 
formed from artificially generated PRP that lacks RBCs but is still fibrin abundant. 
Meanwhile, Casa et al. (2015) suggested that an alternative triad is necessary for SIPA clot 
formation: (i) a collagen surface or other substrate for initial VWF absorption, (ii) a 
pathologically high shear rate for VWF unfolding and elongation, and (iii) platelets and 
VWF in sufficient concentrations (Figure 1-2). Thus, a SIPA clot is mostly composed of 
platelets and VWFs; this is supported by Ku and Flannery (2007)’s study in which 80% of 
SIPA clot was consisted of platelets. SIPA clots look white and are commonly called white 
clots because of the prevalence of platelets and the lack of RBCs. To induce SIPA, many 
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thousands of GPIb-A1 bonds are required to capture platelets under high shear (Wellings 
& Ku, 2012). These bonds may give a SIPA clot a high level of mechanical strength so that 
it can resist the arterial shear rate and blood pressure. 
The high permeability and mechanical strength of a SIPA clot could be a key 
feature that allows it to stabilize in such a high pressure and high shear rate environment 
and hinder the blood flow. In the present study, we aimed to measure SIPA clot 
permeability and mechanical strength using in vitro flow systems and investigate how a 
SIPA clot can block blood flow in an artery. 
 
 
Figure 3-1. Coagulation blood clot modulus from Johnson et al. (2017) and Slaboch 





In order to generate SIPA clots and measure its permeability and mechanical strength, 
controlled flow environments were created via in vitro settings. SIPA clots retrieved from 
the circuits were used to measure modulus and investigate structure. The porous structure 
was studied by taking scanning electron microscope (SEM) and histologic images. 
Measured SIPA clot’s properties were compared to the coagulation clot’s values and 
applied to a simulation to investigate whether a clot can occlude a stenosed coronary artery 
or not. 
3.2.1 In vitro stenotic chambers 
Three different stenotic chambers (Figure 3-2) were used to induce high shear conditions 
and generate SIPA clots of varying shapes and sizes. Based on coronary artery diameter of 
4 mm, each chamber corresponds to 98% stenosis by diameter (microfluidic chamber), 
85% stenosis by diameter (stenotic capillary glass tube, ID = 1.5 mm), and 45% stenosis 
by diameter (stenotic large glass tube, ID = 12 mm) in diameter. Prior to the blood 
perfusion, the stenotic region of each chamber was coated with type 1 fibrillar collagen and 
incubated in a container for 24 hours to generate an adhesive surface. The 12 mm large 
tube (Figure 3-2C) was rotated 180 degrees once after an hour, counting from the moment 
when a collagen solution was added to the tube. 
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Figure 3-2. Geometry of the stenotic chambers: (A) Microfluidic chamber (55% 
stenosis by diameter), (B) Capillary glass tube (ID = 1.5 mm, 65% stenosis by 
diameter), and (C) Large glass tube (ID = 12 mm, 80% stenosis by diameter). (D) 
Photograph of actual test sections showing the size comparison of the three chambers.  
3.2.2 In vitro flow loops for SIPA clot generation 
To generate a SIPA clot, lightly heparinized (3.5 IU/mL) porcine WB was perfused through 
three in vitro flow systems with the three different stenotic chambers. PDMS microfluidic 
and capillary tube were used in single-path in vitro flow systems with two different driving 
protocols: constant pressure or constant flow. 
For the constant pressure experiments (Figure 3-3A), blood flow was driven by a 
constant pressure head of 4.8 mmHg for the microfluidic chamber and 66 mmHg for the 
1.5 mm capillary tube (Ku & Flannery, 2007). In these experiments, mass outflow was 
measured by a precision balance. For the constant flow experiments (Figure 3-3B), the 
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flow rate was controlled using a syringe pump to generate an initial wall shear rate of 3,500 
s−1 in the stenosis (Para & Ku, 2013). The pressure proximal to the stenosis was monitored. 
SIPA clot formation in the stenosis was recorded throughout the experiment using a high-
resolution CCD microscope camera. Meanwhile, a high flow rate (~1 L/min) was required 
to generate a high shear in the large tube (Figure 3-2C). To accommodate this requirement, 
a closed in vitro flow loop was developed with two reservoirs for a constant pressure head 
(30 mmHg) (Figure 3-3C). As the clot grew in the tube, the flow rate of the roller pump 
was manually reduced every 1-2 min and recorded. When the roller pump flow rate reached 
a minimum level (0.05 L/min), the pump was turned off and left the circuit for an additional 
30 minutes to achieve the full occlusion. 
 
Figure 3-3. In vitro flow loops with different flow drivers. A single-path flow driven 
by (A) a constant pressure head or (B) a constant flow rate was used with the 
microfluidic chamber and capillary tube to measure clot permeability and breakage 
strength. (C) A closed loop circuit was developed to generate a clot in a large stenosis 
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that has diameter greater than 2 mm, in order to investigate clot structure and 
mechanical strength. 
3.2.3 Coagulation clot generation 
A non-stenotic capillary tube was coated with type 1 fibrillar collagen and incubated in a 
container for 24 hours to generate an adhesive surface. Porcine blood was treated with 
3.2% sodium citrate (10% in volume) during transportation and recalcified with CaCl2 to a 
final concentration of 10 mM just before placing the blood in the capillary tube (Griffin et 
al., 2019; Matsuo et al., 1981b). 20 μl of re-calcified porcine blood was placed in the 
capillary tube and left still for at least 30 minutes to form a stable red coagulation clot prior 
to the perfusion studies. 
3.2.4 Permeability measurement using Darcy’s law 
In the high shear flow experiments, SIPA clots grew and eventually occluded the channel. 






where κ	is the clot permeability, μ	is the fluid viscosity, Q	is the flow rate, ∆P	is the pressure 
difference across the clot, L	is the clot length, and A	is the clot cross-sectional area. In this 
calculation, the clot was modeled as a cuboid or cylindrical porous block in the 
microfluidics chamber or capillary tube, respectively ( 
Figure 3-4). The values of L	and A	are	extracted	from the image data and used a constant 
blood	viscosity	of	3.5 cP.  
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For the constant pressure head-driven experiments, outlet mass was measured over 
perfusion time and corrected by reflecting evaporation at the reservoir surface (Figure 3-5). 
The flow rate was calculated from the curve-fitted mass outflow for 10 minutes 
(microfluidic chamber) or 1 hour (capillary tube) after the occlusion. For the constant flow 
rate experiment, the maximum pressure proximal to the clot was measured by a pressure 
transducer and used to calculate the permeability. To measure red coagulation clot 
permeability, air was used as a fluid and perfused by a syringe pump with a constant flow 
rate of 0.002 mL/min. The pressure proximal to the clot was used to calculate the 
permeability. 
 
Figure 3-4. Parameters from perfusion images for the permeability calculation using 
Darcy’s law. (A) Cuboid porous medium modeling the clot in the microfluidic 
chamber. (B) Cylindrical porous medium modeling the clot in the capillary tube. 
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Figure 3-5. Outlet mass measured (blue) along the perfusion time in (A) the 
microfluidic chamber and (B) the capillary tube. Evaporation at the reservoir surface 
is reflected, and the corrected outlet mass is shown in red line. 
3.2.5 Multi-channel analysis 
SIPA clot is modelled as a porous media with multi cylindrical channels. Assuming 










where μ	is the fluid viscosity, L	is the clot length, and dp	is the channel diameter. Pressure 








where κ	is the clot permeability,	A	is the cross-section area, and np	is the number of channels 


















3.2.6 Breakage strength measurement 
With a syringe pump, constant flow was induced into the stenotic chambers to generate a 
SIPA clot. The pressure upstream increased as the SIPA clot grew at the stenotic region; 
eventually, the clot broke off was transported to the downstream reservoir. After the 
breakage, the SIPA clot regrew and reoccluded the chamber. Therefore, the broken part 
was not the collagen-glass wall interface. The blow-out pressure when the clot was 
breaking off was used to calculate the breakage strength of the clot. The clot was modelled 
as a homogeneous material that fully occluded the chamber, as shown in Figure 3-6.  The 
forces acting on the clot were calculated as follows: 
 𝐹" = 𝜋𝑟, ∙ ∆𝑃 (12) 
 𝐹, = 𝜋𝑟 ∙ 𝐿 ∙ 𝜏 (13) 
where r denotes radial distance, ∆P	is the pressure difference across the clot, L	is the clot 







The maximum stress occurs at the most-outer edge (r = R) of the clot; this was 
confirmed in the experiments, as the clots were found to be broken as a big piece. The 






Figure 3-6. Forces acting on an occlusive clot in a stenotic chamber. (A) Two-
dimensional and (B) three-dimensional views of forces and parameters on an 
occlusive clot. 
3.2.7 Computational fluid dynamics and finite element analysis 
CFD was used to predict the shear rate distribution within the large glass tube. A simulation 
was performed using Ansys 19.1 (Ansys Inc., PA, USA). Whole blood (WB) flow was 
assumed to be a Newtonian fluid of 3.5 cP, and the flow was presumed to be laminar, 
incompressible, steady, continuum, and isothermal based on the Reynolds number (=1,400) 
of the experiments. The no-slip boundary condition was applied to the walls, and a 0.66 
L/min flow rate was applied at the inlet with zero pressure at the outlet (Figure 2-3B). Mesh 
convergence was achieved at 0.6 million hexagonal cells. To simulate pressure distribution 
and flow rate after a SIPA clot formation, a porous media was added to the CFD model 
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(light blue, Figure 3-7). With the clot, the simulation converged with 2.6 million hexagonal 
cells. The calculated pressure distribution was transferred to Ansys Static Structural 
module (Ansys Inc., PA, USA) for a finite element (FE) analysis. The analysis was 
simplified by applying a 2-D axisymmetric condition (Figure 3-8). A fixed support 
boundary condition was applied at the interface between the clot and channel wall and the 
pressure distribution from CFD results was applied at the upstream and downstream clot 
surfaces. Mesh convergence was achieved at 0.1 million tetragonal cells. 
 
Figure 3-7. A porous media CFD model with a clot (light blue) located at the stenosis. 
 
Figure 3-8. A 2-D axisymmetric model for a simulation of clot deformation and stress 
distribution. (A) A fixed support boundary condition was applied at the interface 
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between the clot and channel wall. Calculated pressure was applied on (B) proximal 
and (C) distal clot surfaces. 
3.2.8 Histology and immunohistochemistry 
Blood clots were fixed in formalin and embedded in paraffin for further histological and 
immunohistochemical analyses. The paraffin block holding the clot was cut into 5 µm-
thick slices and deparaffinized. Using Carstairs’s staining method, platelets were colored 
in light blue, fibrins in red, RBCs in yellow, and white blood cells (WBCs) in black. VWF 
was stained in brown using immunohistochemistry, and counterstaining was performed 
using Meyer’s haematoxylin. 
3.2.9 Scanning electron microscope imaging 
Blood clots were fixed in a 10% formalin solution for more than 24 hours. A fixed blood 
clot was submerged into successive ethanol solutions of 25%, 50%, 75%, 80%, and 90% 
concentrations for 15 min each and rinsed with DI water. After an overnight air dry, the 
sample was sputter coated with Au and imaged using a SEM (Hitachi SU8230). 
3.2.10 Dynamic mechanical analysis 
Dynamic mechanical analysis (DMA) was performed on blood clots using an ElectroForce 
3100 (TA instruments, New Castle, DE). Three displacements (0.1 mm, 0.2 mm, and 0.5 
mm) and three different frequencies (0.1 Hz, 1 Hz, and 10 Hz) were applied to observe the 
displacement dependency and quantify the frequency response (Figure 3-9). The 
compressive modulus was calculated from the magnitude of displacement curve and the 
force response curve per the usual definitions for DMA. 
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Figure 3-9. Input displacement for DMA of the blood clots. 
3.2.11 Analysis 
A one-way ANOVA was used to test for statistical differences between groups with the 
significance set at p	<	0.05 (GraphPad Prism 7, GraphPad Software, San Diego, CA). All 
data are presented as the mean ±	standard deviation unless otherwise noted. 
3.3 Results 
3.3.1 A SIPA clot is more permeable than a coagulation clot 
The SIPA clots were all significantly more permeable than the coagulation clots (Figure 
3-10). Wufsus et al. (2013) quantified the permeability of platelet-rich clots formed under 
static conditions with platelet volume fractions ranging from 0.31 to 0.61. The coagulation 
clot permeability measured in the present study was 5×10−4 ±	5×10−4 μm2, which fits in the 
permeability range reported by Wufsus et al. (2013) (1.5 ×	10−5  ±	3.3 ×	10−6 to 6.1 ×	10−3 ±	
1.1 ×	10−3 μm2). On average, the SIPA clot was three orders of magnitude more permeable 
(0.3 ±	0.4 μm2) than the red coagulation clot (5 ×	10−4 ±	5 ×	10−4 μm2). 
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Kobayashi et al. (2016) used the same microfluidic chamber design and a constant 
pressure head of 4.8 mmHg and observed RBCs passing through the SIPA clot that 
developed. The velocity of the RBCs moving through the channels in the clot can be used 
to calculate its permeability. The velocity of the RBCs traveling in the central part of the 
channel was used as a superficial velocity (v = Q/A) in equation (5) to estimate the 
permeability (Figure 3-10; Kobayashi 2016). There was no statistical difference between 
the permeability calculated using Kobayashi et al. (2016)’s measurements and those 
obtained in our microfluidic chamber with a constant pressure head.  
 
Figure 3-10. Permeability measurement results of the SIPA clot and coagulation clots. 
Wufsus et al. (2013) measured the permeability of coagulation clots with platelet 
concentrations of (1) 61% and (2) 31%. Compared to the coagulation clots, the SIPA 
clots showed significantly higher permeability (p < 0.05). 
The permeabilities of the SIPA clots formed in the constant pressure experiments 
were lower than the permeabilities of those formed in the constant flow experiments. For 
the microfluidic chamber, the permeability	was	0.5 ±	0.46 μm2 for the constant pressure 
experiments but 2.6 ±	1.2 μm2 for the constant flow experiments; for the capillary tube, the 
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permeability	was	9.4 ×	10−2 ±	5.9 ×	10−2 μm2 vs. 17.5 ±	4.3 μm2 for the constant pressure 
and flow experiments, respectively.  
Under the constant flow condition, extremely high shear rates can be generated as 
a clot grows over time, and these extremely high shears may limit the thrombus growth. 
Limited thrombus growth can generate a gap (microfluidic chamber) or a hole (capillary 
tube) in the thrombus, which increases its average permeability (Figure 3-11A&B). The 
average hydraulic resistance is the parallel sum of the SIPA clot resistance (Rc) and the 
resistance of the large hole at the center (Rp). Thus, assuming Poiseuille’s flow, the effect 
of the gap or the hole was excluded by simulating the gap height or measuring the hole 
diameter and subtracting its hydraulic resistance from the total value. When the effect of 
the gap or the hole was excluded, the permeability decreased and became close to the 
constant pressure results (Figure 3-11C).  
 
 47 
Figure 3-11. SIPA clot growth simulation of (A) the microfluidic chamber and (B) the 
capillary tube showing that the constant pressure condition completely occludes the 
channels, while the constant flow condition leaves (A) a gap or (B) a hole at the center. 
(C) SIPA clot permeability with the reflected effect (i.e., gap or hole) (*). 
 
3.3.2 Porous structure of SIPA clot 
Average values of measured clot length, cross section area, pressure head, and mass flow 
rate are summarized in Table 2. In microfluidic chamber, the clot length was more than 3 
times longer when constant flow condition was applied compared to constant pressure. 
Mass flow rate was 3 to 5 orders of magnitude higher with constant flow condition than 
constant pressure for both high shear chambers. Multi-channel analysis was performed 
using values from Table 2, showing pore diameters ranging from 1 to 100 and pore numbers 
ranging from 1 to 100,000 (Figure 3-12). Kobayashi et al. (2016) observed RBCs (diameter 
= 6-8 µm) traveling through the SIPA clot, thus pore diameters are approximately 8 µm 
giving a porosity of about than 60% from ~5,000 pores. 
Table 2. Average values of measured clot parameters and calculated permeability. 










+ Pressure 0.09 0.039 4.78 0.04 0.49 
Microfluidics  
+ Flow 0.31 0.039 160 1.67 2.63, 1.5* 
Capillary  
+ Pressure 0.89 0.12 66 0.03 0.09 
Capillary  
+ Flow 0.83 0.1 260 1252 17.5, 2.76*  
* SIPA clot permeability with the reflected effect of gap or hole (Figure 3-11C). 
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Figure 3-12. Multi-channel analysis result of SIPA clot. (A) Pore diameter ranged 
from 1 to 100 and (B) pore number ranged from 1 to 10,000. 
 
3.3.3 SIPA clot has greater breakage strength than coagulation clot 
In average, SIPA clot resisted pressure gradient of 160 mmHg for microfluidics and 260 
mmHg for capillary tubes. In turn, the SIPA clots demonstrated an breakage strength of 4.6 
± 1.3 kPa, which was 7 times significantly stronger than the coagulation clots, which had 
an breakage strength of 0.63 ± 0.3 kPa (Figure 3-13, p < 0.05). The type of stenotic chamber 
difference did not significantly change the breakage strength of the SIPA clots 
(microfluidic vs. capillary tube). And the surface with or without collagen type 1 did not 
significantly impact the breakage strength of the coagulation clots. 
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Figure 3-13. The SIPA clots showed significantly higher breakage strength (* p < 0.05) 
than the coagulation clots. The presence (n = 3) or absence (n = 3) of a collagen surface 
did not significantly impact coagulation clot strength. Whether the stenotic chamber 
was a microfluidic chamber (n = 7) or a capillary tube (n = 7) did not significantly 
changed SIPA clot breakage strength. 
3.3.4 A SIPA clot generation in a closed flow loop 
Porcine WB was perfused into a closed in vitro flow loop (Figure 3-3C) to generate a large 
SIPA clot in order to investigate its structure and mechanical strength. The large glass tube 
( Figure 3-14A) had an inner diameter of 12 mm and 80% stenosis in diameter. Reynolds 
number was 334 (Table 3) and flow separation was seen during perfusion similar to the 
capillary tube experiment where Re = 162. Flow separation was not found in the 
microfluidic experiment where Re = 2.5. The white SIPA clot grew over time at the stenosis 
( Figure 3-14B), and the roller pump was manually adjusted to reduce the flow rate (Figure 
3-15A). The maximum shear rate reached over 10,000 s-1 with the initial flow rate (Figure 
3-15B), which is higher than microfluidics (Figure 2-3) or capillary tube but still in the 
range where RPA can occur (Mehrabadi et al., 2016). Eventually, the clot occluded the 
chamber and ceased the blood flow in 60 ± 17 minutes. All occlusive SIPA clots had a 
similar trumpet-like shape with the mouth opened against the flow (Figure 3-14C). Using 
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Mehrabadi et al. (2016)‘s high shear thrombosis model (described in Ch2.2.2), the flow 
rate was simulated with the initial flow rate value from the experimental data (0.66 L/min). 
The simulated flow rate was lower in the 10-60-minute time frame but fell in the range of 
error and reached flow rate below 5 mL/min in 71 minutes (Figure 3-15A). 
Table 3. Reynolds number and occlusion time of three high shear chambers with 
constant pressure head driven flow. 
 Microfluidics Capillary tube Large tube 
Minimum length scale [mm] 0.082 0.4 2 
Reynolds number 2.5 162 334 
Occlusion time [min] 1.4 ± 0.22 9.3 ± 0.9 60 ± 17 
 
 Figure 3-14. (A) Stenosed large glass tube coated with collagen type 1. (B) The SIPA 
clot shown in white formed at the stenosis region. (C) The SIPA clot boundary is 
highlighted in yellow. 
 
 51 
Figure 3-15. (A) Flow rate over time from the experiment (red, n = 11) and the 
simulation (blue). (B) Using the average value of the initial flow rate, CFD showed a 
maximum shear rate of 10,083 s-1 at the initial stage of perfusion. 
3.3.5 Platelets are tightly packed in a SIPA clot 
After the flow circuit was drained, the SIPA clot was retrieved (Figure 3-16A) from the 
large glass tube for the SEM imaging. The retrieved clot had a similar trumpet-looking 
shape to the one observed during the blood perfusion (Figure 3-14) and had different colors 
in characteristic regions. At the upstream and the downstream, there were transparent 
yellow parts that were originally detached from the glass wall. These parts initially had 
sheet-like morphology but were folded and tangled after the detachment. Right next to 
these regions were dark red colors that were expected to contain many RBCs. Lastly, the 
central part where the stenosis had been located had a light red or pink color. This stenotic 
region was expected to incorporate billions of platelets because SIPA was expected to 
occur here.  After formalin fixation and dehydration (Figure 3-16B), the clot was cut in 
half in the flow direction to image the inner part of the clot (Figure 3-16C). The cross-
section showed a finger- or mountain-like structure protruding towards the lumen (Figure 
3-16D & E). This mountain structure was not found in the SEM images. To compare each 
region, the clot was split into four regions for low magnification images and nine ROIs (A-
I) for moderate to high magnification images (Figure 3-16F). Geological shapes were seen 
in the low magnification images (Figure 3-17 to Figure 3-20) with layers of aggregates and 
some fibers. Meanwhile, the moderate magnification images displayed aggregates of 
numerous spheres that were approximately 2 µm in diameter, which were expected to be 
platelets (Figure 3-21 to Figure 3-38). The platelet aggregates were well captured in the 
high magnification images. Regions E, F, and G, where SIPA was expected to be maximal, 
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showed tightly packed platelets. To quantify how many platelets were packed in the clot, 
recognizable spheres with a diameter greater than 1.5 µm were manually counted in the 
high magnification SEM images. The G region had the highest density of spheroid platelets 
(0.23 platelets/µm2), while the I region had the lowest (0.01 platelets/µm2) (Figure 3-39). 
In the stenotic region (C-G), D region showed the lowest platelet density compared to the 
other regions. In Figure 3-28, D region is occupied with smooth surfaces and small granules 
that have a diameter less than 1 µm, presumably activated platelets and platelet-released 
granules. Assuming 2 µm platelet thickness and an average value of 0.1 platelets/µm2, 
platelet density per volume is 0.05 platelets/µm3 and the total SIPA clot was calculated to 
contain 1.23 billion platelets.  
 
Figure 3-16. (A) A SIPA clot retrieved from the large glass tube was (B) formalin 
fixed and (C) dehydrated using ethanol and cut in half to expose cross section. (D) 
Magnified view of stenotic part of the clot. (E) Platelet-rich white region is highlighted 
in green showed mountains of platelet aggregates (white arrows). (F) Regions of 




Figure 3-17. SEM image of the SIPA clot (R1). 
 
Figure 3-18. SEM image of the SIPA clot (R2). 
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Figure 3-19. SEM image of the SIPA clot (R3). 
 
Figure 3-20. SEM image of the SIPA clot (R4). 
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Figure 3-21. SEM image of the SIPA clot (A). 
 
Figure 3-22. SEM image of the SIPA clot (A) with high magnification. 
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Figure 3-23. SEM image of the SIPA clot (B). 
 
Figure 3-24. SEM image of the SIPA clot (B) with high magnification. 
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Figure 3-25. SEM image of the SIPA clot (C). 
 
Figure 3-26. SEM image of the SIPA clot (C) with high magnification. 
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Figure 3-27. SEM image of the SIPA clot (D). 
 
Figure 3-28. SEM image of the SIPA clot (D) with high magnification. 
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Figure 3-29. SEM image of the SIPA clot (E). 
 
Figure 3-30. SEM image of the SIPA clot (E) with high magnification. 
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Figure 3-31. SEM image of the SIPA clot (F). 
 
Figure 3-32. SEM image of the SIPA clot (F) with high magnification. 
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Figure 3-33. SEM image of the SIPA clot (G). 
 
Figure 3-34. SEM image of the SIPA clot (G) with high magnification. 
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Figure 3-35. SEM image of the SIPA clot (H). 
 
Figure 3-36. SEM image of the SIPA clot (H) with high magnification. 
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Figure 3-37. SEM image of the SIPA clot (I). 
 
Figure 3-38. SEM image of the SIPA clot (I) with high magnification. 
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Figure 3-39. Unactivated platelet density of each region taken by SEM. 
 
3.3.6 A SIPA clot is VWF-platelet-rich and has a porous structure 
Two SIPA clots were stained using the Carstairs or VWF immunostaining method. One 
clot was sectioned in a longitudinal direction, and the other was sliced in a transverse 
direction. Consistent with the SEM results in Ch3.3.5, Carstairs staining showed that the 
SIPA clot was dominantly occupied by platelets (blue, Figure 3-40) and immunostaining 
result displayed that VWF was present throughout the SIPA clot (Figure 3-41), proving 
that the SIPA clot is VWF and platelet rich. Meanwhile, although coagulation cascade can’t 
occur due to pathological high shear conditions as discussed in CH1.3, the Carstairs 
staining also revealed a little RBCs (yellow) and fibrin (red) in the clot (Figure 3-40). 
Presumably, RBCs become trapped and fibrin was formed in stagnant regions after 
occlusive SIPA clot formation. Thus, the void region and the space occupied by RBCs and 
fibrin are assumed to be pores or valleys that were formed during SIPA clot formation. 
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The SIPA clots were similar in appearance, macroscopically, as is seen in Figure 
3-16. To explore each structure in detail, the clot was separated into six regions (L1 to L6, 
Figure 3-42A); the transparent parts at the each end (L1 and L6, Figure 3-42A) had fewer 
platelets than the central part of the clot, but these parts had more fibrin (Figure 3-43) and 
VWF (Figure 3-44). In addition, dispersed platelet aggregates were surrounded by fibrins 
(Figure 3-45, Figure 3-46, and Figure 3-61). In L2 (Figure 3-42A), the platelets and trapped 
RBCs formed a stripe-like pattern (Figure 3-47). Similar to L1 and L6, the platelet 
aggregates were surrounded by fibrin and the RBCs were trapped in the space between the 
platelet aggregates (Figure 3-49). L3 and L4 were stenosis regions, where the highest shear 
rate and SIPA were expected to occur. These regions had axisymmetric structures with 
fewer trapped RBCs than L2, and the fibrins were concentrated at the center of the lumen 
(Figure 3-50 and Figure 3-52). In addition, a color gradation from light blue to dark blue 
to medium blue was seen from the wall to the center of lumen (Figure 3-52). L5 showed 
characteristic features in that the platelet aggregates were at the wall and protruded at the 
center, and the area between these regions was filled with RBCs and fibrin (Figure 3-55). 
The other SIPA clot was sectioned in a transverse direction and stained using the 
Carstairs and VWF immunostaining method (T1 to T9, Figure 3-42B). Section T1 shows 
a large number of trapped RBCs and a small number of dispersed platelet aggregates with 
fibrins (Figure 3-62) and VWFs (Figure 3-63), which were found in L1. Section T2 shows 
a large hole at the center and trapped RBCs and some fibrins in the pores (Figure 3-64). 
The stenotic regions in sections T3 to T7 reveal lumen that were completely occluded by 
platelet aggregates with a number of pores filled with RBCs and fibrins (Figure 3-66 to 
Figure 3-74). In contrast, sections T8 and T9 have an RBC-rich region between the platelet 
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aggregates at the wall and the center of the lumen; this feature is consistent with L5 in the 
longitudinal slide (Figure 3-55). Color segmentation analysis of the histological images of 
the blood clots indicated differences in composition and porosity (Figure 3-80). SIPA clot 
was rich in platelets (60%) and had little fibrin of 4% whereas WB clot was RBC-rich 
(70%) and PRP clot was platelet-rich (90%) but not as porous as SIPA clot (5% vs. 37%). 
Summarizing the findings from histology and SEM, the occluding middle section 
(L2-5 and T2-9 in Figure 3-42) was composed of dense platelets and VWF with little fibrin 
and many channels ranging from 10 to 100 µm. Histological images showed more than 
70% of this middle section was platelets, implying that the SEM area without spherical 
platelets could be occupied by flat, activated platelets. The entrance region (T1) and exit 
region (T6) showed long VWF strands without large platelet aggregates under shear rates 
less than 1,400 s-1 (Figure 3-15B). Stripes of platelet aggregates and trapped RBCs were 
found in L2 and L5, where more unactivated platelets found in these regions (A, B, and G) 
than L3-4 (C-F). Platelets in region L3-4 (C-D) were mostly misshapen consistent with 
prior activation, as this region is expected to experience high shear rate up to 9,000 s-1 
(Figure 3-15B). The end of thrombus (R5 and T8-9) showed a protruding central core of 
dense platelets that appear not to have activated where the SEM images are of captured, 
round platelets (G). Surrounding the core was an annulus without thrombus where 
recirculation and low shear rate is expected to occur. At the wall is a thin ring of VWF and 
small aggregates hugging the surface and extending throughout the recirculation region. 
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Figure 3-40. Carstairs staining of the SIPA clot in the longitudinal direction. 
 
Figure 3-41. VWF staining of the SIPA clot in the longitudinal direction. 
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Figure 3-42. (A) Regions of interest from the longitudinal slide (L1-6). (B) 
Approximate locations of the cross sections (T1-8). 
 
Figure 3-43. Carstairs staining of the SIPA clot in the longitudinal direction  
(L1, 5x magnification). 
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Figure 3-44. VWF staining of the SIPA clot in the longitudinal direction  
(L1, 5x magnification). 
 
Figure 3-45. Carstairs staining of the SIPA clot in the longitudinal direction  
(L1, 40x magnification). 
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Figure 3-46. Carstairs staining of the SIPA clot in the longitudinal direction  
(L1, 100x magnification). 
 
Figure 3-47. Carstairs staining of the SIPA clot in the longitudinal direction (L2, 5x 
magnification). Arrows indicate mountains (black) and valleys (yellow).  
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Figure 3-48. Carstairs staining of the SIPA clot in the longitudinal direction  
(L2, 40x magnification). 
 
Figure 3-49. Carstairs staining of the SIPA clot in the longitudinal direction  
(L2, 100x magnification). 
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Figure 3-50. Carstairs staining of the SIPA clot in the longitudinal direction  
(L3, 5x magnification). Arrows indicate mountains (black) and valleys (yellow). 
 
Figure 3-51. Carstairs staining of the SIPA clot in the longitudinal direction  
(L2, 40x magnification). 
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Figure 3-52. Carstairs staining of the SIPA clot in the longitudinal direction  
(L4, 5x magnification). Arrows indicate mountains (black) and valleys (yellow). 
 
Figure 3-53. Carstairs staining of the SIPA clot in the longitudinal direction  
(L4, 40x magnification). 
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Figure 3-54. Carstairs staining of the SIPA clot in the longitudinal direction  
(L4, 100x magnification). 
 
Figure 3-55. Carstairs staining of the SIPA clot in the longitudinal direction  
(L5, 5x magnification). Arrows indicate mountains (black) and valleys (yellow). 
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Figure 3-56. VWF staining of the SIPA clot in the longitudinal direction  
(L5, 5x magnification). 
 
Figure 3-57. Carstairs staining of the SIPA clot in the longitudinal direction  
(L5, 40x magnification). 
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Figure 3-58. Carstairs staining of the SIPA clot in the longitudinal direction  
(L5, 100x magnification). 
 
Figure 3-59. Carstairs staining of the SIPA clot in the longitudinal direction  
(L6, 5x magnification). 
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Figure 3-60. Carstairs staining of the SIPA clot in the longitudinal direction  
(L6, 40x magnification). 
 
Figure 3-61. Carstairs staining of the SIPA clot in the longitudinal direction  
(L6, 100x magnification). 
 78 
 
Figure 3-62. Carstairs staining of the SIPA clot in the transverse direction  
(T1, 5x magnification). 
 
Figure 3-63. VWF staining of the SIPA clot in the transverse direction  
(T1, 5x magnification). 
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Figure 3-64. Carstairs staining of the SIPA clot in the transverse direction  
(T2, 5x magnification). 
 
Figure 3-65. VWF staining of the SIPA clot in the transverse direction  
(T2, 5x magnification). 
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Figure 3-66. Carstairs staining of the SIPA clot in the transverse direction  
(T3, 5x magnification). 
 
Figure 3-67. VWF staining of the SIPA clot in the transverse direction  
(T3, 5x magnification). 
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Figure 3-68. Carstairs staining of the SIPA clot in the transverse direction  
(T4, 5x magnification). 
 
Figure 3-69. VWF staining of the SIPA clot in the transverse direction  
(T4, 5x magnification). 
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Figure 3-70. Carstairs staining of the SIPA clot in the transverse direction  
(T5, 5x magnification). 
 
Figure 3-71. VWF of the SIPA clot in the transverse direction  
(T5, 5x magnification). 
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Figure 3-72. Carstairs staining of the SIPA clot in the transverse direction  
(T6, 5x magnification). 
 
Figure 3-73. VWF of the SIPA clot in the transverse direction  
(T6, 5x magnification). 
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Figure 3-74. Carstairs staining of the SIPA clot in the transverse direction  
(T7, 5x magnification). 
 
Figure 3-75. VWF staining of the SIPA clot in the transverse direction  
(T7, 5x magnification). 
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Figure 3-76. Carstairs staining of the SIPA clot in the transverse direction  
(T8, 5x magnification). 
 
Figure 3-77. VWF staining of the SIPA clot in the transverse direction  
(T8, 5x magnification). 
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Figure 3-78. Carstairs staining of the SIPA clot in the transverse direction  
(T9, 5x magnification). 
 
Figure 3-79. VWF staining of the SIPA clot in the transverse direction  
(T9, 5x magnification). 
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Figure 3-80. Histological analysis of (A) WB and (B) PRP coagulation clots, and (C1) 
a SIPA clot. Color segmentation of the SIPA clot displayed (C2) platelets, (C3) fibrins, 





3.3.7 A SIPA clot is rich in VWF, especially near the wall  
Prevalence of VWFs (brown) were found in the SIPA clot compared to PRP clot (Figure 
3-81). In the longitudinal and transverse directions, the immunostaining results showed 
that VWFs were concentrated at the edge where the clot adjoined the wall (Figure 3-82A). 
In contrast, in the Carstairs staining result, the blue coloring was lighter near the wall, 
indicating that fewer platelets were aggregated at the lag phase when platelet adhesion 
occurred (Figure 3-82B). This complementary density of VWF and platelet was confirmed 
in Figure 3-82C, which plots normalized intensity level of VWF and platelet from wall to 
the lumen. Therefore, when the SIPA clot started to develop, a large amount of VWFs must 
have been accumulated first in order to capture the marginated platelets. The thickness of 
this layer density was about 20 µm, which had fewer platelets and larger amount of VWF.  
 





Figure 3-82. (A) VWF staining and (B) Carstairs staining of a SIPA clot in the 
transverse direction (Section T6, 10x magnification). (C) Normalized intensity level 
along the red lines in (A) and (B). Near the wall, VWF was concentrated and dark, 
yielding low intensity levels; whereas, Carstairs platelet was light at the wall 
corresponding to a high intensity level. Black arrows indicate the starting point close 






3.3.8 A SIPA clot is stiffer than a coagulation clot 
Dynamic Mechanical Analysis (DMA) was conducted on 1) coagulation clots with RBCs 
(WB) and 2) without RBCs (PRP) as well as 3) SIPA clots (Figure 3-83). Three different 
displacements (0.1 mm, 0.2 mm, and 0.5 mm) and three different frequencies (0.1 Hz, 1 
Hz, and 10 Hz) were applied to each clot. All clots showed elastic behavior with a small 
phase difference in 0.1-1 Hz range (Figure 3-83) but displayed a viscoelastic response to 
10 Hz displacements. The SIPA clots demonstrated the highest compressive modulus for 
all conditions compared to the WB and PRP coagulation clots (Figure 3-84). On average, 
the SIPA clot (2.9 ± 1.9 kPa) had a 2.4 times higher compressive modulus than the WB 




Figure 3-83. DMA result showing SIPA clot force response to a 0.2 mm displacement 





Figure 3-84. Blood clot compressive modulus measured by DMA. On average, clots 
had an initial height of 1.8 mm. Three different displacements were applied on the 
blood clots ((A): 0.1 mm. (B): 0.2 mm. (C): 0.5 mm). The SIPA clots showed a two-
fold higher modulus (2.9 ± 1.9 kPa, n = 3) compared to the WB (n = 3, 1.2 ± 0.9 kPa) 
and PRP (0.8 ± 0.5 kPa, n = 3) clots. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 
0.0001. 
 
3.3.9 Clot deformation and critical lengths for the arterial occlusion 
An occlusive clot formed in a vessel needs to resist blood pressure to stop blood flow. CFD 
was performed to calculate the flow field around a clot after occlusion. The SIPA clot and 
coagulation clot were modeled as a porous media with different permeability (0.3 µm2 vs. 
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0.0005 µm2) and porosity (37% vs. 25%). The difference in permeability did not 
significantly change pressure distribution, less than 1 Pa due to pressure boundary 
conditions. However, SIPA clot and coagulation clot had significantly different flow rate 
(5 nl/min vs. 13 pl/min) and maximum blood velocity through the clot (2.2 m/s vs. 0.5 
µm/s). The calculated pressure distribution (Figure 3-85) was transferred for a FE analysis 
to quantify clot deformation and stress distribution. The SIPA clot showed maximum 
deformation of 1.4 mm at the center (Figure 3-86) and stress of 5 kPa at the tip where the 
clot is interfacing wall (Figure 3-87). Most clot areas were having stress less than the 
breakage strength (4.6 kPa). The morphology after the deformation was similar to the 
histologic image (Figure 3-40). Meanwhile, the coagulation clot deformed more than 3 mm 
at the center, making the clot extremely skewed towards downstream (Figure 3-88). The 
coagulation clot was experiencing stress beyond its breakage strength (675 Pa); thus, it 
cannot block the channel and will eventually break off (Figure 3-89). 
 Silver, Baroldi, and Mariani (1980) found occlusive thrombosis most often 
occurred in 70-89 % stenosed (by diameter) coronary artery. In addition, they found an 
occlusive thrombus can form in a 5-mm length stenosis. Assuming a rigid clot, 175 mmHg 
blood pressure (Stamler et al., 1989), and using breakage strength obtained from Ch 3.3.3, 
a critical length that would be required for a clot to occlude a stenosed coronary artery was 
calculated (Table 4). A SIPA clot would have sufficient strength to occlude a 60-90% 
stenosed (by diameter) coronary artery with a clot length shorter than 3 mm. Meanwhile, a 
coagulation clot would need a length longer than 10 mm for a 60-70% stenosis or 3 mm 
for an 80-90 % stenosis. 
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Figure 3-85. Pressure contour in a stenosed tube with a blood clot. 
 
 
Figure 3-86. SIPA clot FE result showed maximum deformation of 1.4 mm. 




Figure 3-87. SIPA clot FE result showed stress less than its breakage strength (4.6 
kPa). Undeformed state is shown as a gray contour. 
  
Figure 3-88. Coagulation clot FE result showed maximum deformation of 3.3 mm. 
Undeformed state is shown as a gray contour. 
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Figure 3-89. Coagulation clot FE result showed more than 39% area having a stress 
higher than its breakage strength (675 Pa). Undeformed state is shown as a gray 
contour. 
 
Table 4. Critical clot length for coronary occlusion based on the breakage strength of 
the thrombus. 
mm  
Stenosed coronary by diameter 
60% 70% 80% 90% 
Vessel diameter 1.6 1.2 0.8 0.4 
SIPA clot length 2.0  1.5  1.0  0.5  






The SIPA clots were three orders of magnitude more permeable than the coagulation clots 
(0.3 µm2 vs. 0.0005 µm2). Despite high in platelet density (57%), the SIPA clot’s 
permeability is two orders of magnitude higher permeability compared to 31% platelet-rich 
coagulation clot (0.0061 µm2) by Wufsus et al. (2013). The high permeability may help the 
SIPA clot to relieve flow pressure and continue to grow. The permeability of the clot is 
strongly related to the thrombolytic drug delivery to the clot (Diamond, 1999). A previous 
study has used the value of a coagulation clot’s permeability to estimate the thrombolysis 
time (Piebalgs et al., 2018); however, the change in permeability for a SIPA clot will likely 
result in significantly different thrombolysis time. Based on the permeability value in 
Figure 3-10, porosity was estimated using multi-channel modelling in this study. The 
porosity from the histology images (37%) was in the range of the theoretically calculated 
maximum porosity value (60%), implying that the SIPA clot’s porous structure is 
equivalent to 1,000 pores with an approximate diameter of 10 µm. These values are in good 
agreement with what Arrarte Terreros et al. (2020) found in their clinical study. They 
calculated permeability of occlusive thrombi in acute ischemic stroke patients by 
measuring flow rate and assuming a range of pressure gradient from 30 to 100 mmHg. 
They arrived at conclusions that the thrombus permeability ranges from 19.2 µm2 to 64 
µm2, the number of channels in the thrombus ranges from 449 to 1,497, and the channel 
radius ranges from 12 µm to 22 µm. Thus, the occlusive thrombi found in acute ischemic 
stroke patients must be SIPA clot, not coagulation clot. 
 The present findings indicate that a SIPA clot has 7 times higher breakage strength 
(4.6 kPa vs. 0.6 kPa) and 2.5 times higher stiffness (3.2 kPa vs. 1.2 kPa) than a WB 
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coagulation clot. Compared to Riha et al. (1999), the measured breakage strength (0.3 kPa 
vs. 0.6 kPa) and stiffness (0.4 kPa vs. 1.2 kPa) of coagulation clots were higher in our study. 
They tested coagulation clots immediately after mixing calcium chloride, thus fibrin 
polymerization could have been immature to provide a higher strength; whereas, our study 
allowed 30 min to 1 hr for the coagulation clot to be polymerized.  
The SIPA clot may have more strength than coagulation clots from the components 
or the architecture. The protein strands of VWF and fibrin are likely similar in strength, as 
well as the cell membranes of platelets and erythrocytes, so the components are similar. 
CFD models of SIPA aggregation indicate that multiple strands of VWF roll up individual 
platelets into agglomerates (Z. Liu, 2020). Coagulation clots likely form by single fibrin 
strands connecting RBC during static conditions. Thus, the seven-fold increase in strength 
may stem from the architecture of greater numbers of VWF tethers forming the SIPA 
aggregate. Alternatively, the interface between components rather than the component 
itself may break off. Lam et al. (2011) did a single platelet measurement by using atomic 
force microscopy cantilever coated with fibrinogen, and found a rupture occurred at the 
interface when stress reached 5 kPa. Meanwhile, Wellings and Ku (2012) suggested that a 
VWF net can capture a platelet under high shear via numerous Gp1b-A1 bonds that have 
strength of ~ < 100 pN. A concave VWF net can create 11,280 bonds, which can be 
converted to a strength of 100 kPa. Moreover, more GPIIb/IIIa bonds can form and give 
additional strength between platelet-VWF interface after a platelet activation. Thus, the 
strength may derive from the increased number of bonds per platelet during SIPA. 
With the measured stiffnesses of a SIPA clot, our FE model showed that the center 
of SIPA thrombus facing the flow deforms about a same magnitude (1.4 mm) compared to 
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histologic images (1.2 mm) and can block the large stenotic glass tube. In contrast, a 
coagulation clot would deform more than 3 mm and have a large area having stress that 
exceeds its breakage strength. Using our calculated breakage strengths of blood clots, a 
critical length for a clot to occlude stenosed coronary artery was estimated and compared 
to clinical data (Silver et al., 1980; Stamler et al., 1989). A SIPA clot would be strong 
enough to resist an arterial blood pressure (175 mmHg) and occlude the artery with a length 
of 2 mm. In contrast, a coagulation clot would be required to be longer than 10 mm clot 
length for ~70% stenosis in diameter and 3 mm clot length for ~90 % stenosis in diameter. 
Thus, it is unlikely that a coagulation clot could account for an arterial occlusion as it would 
need to be much longer than generally observed at autopsy. However, a coagulation clot 
may form after the SIPA clot occludes an artery, proximal and distal to the SIPA clot. Thus, 
a pathological post-mortem specimen may be mixture of SIPA clot and coagulation clot, 
especially if there was time delay between the occlusion and a clot retrieval. This may 
explain why people have been reported finding fibrin clots in coronary arteries (Uchida et 
al., 2011) or carotid arteries (Marder et al., 2006), after late harvest making hard to 
distinguish the real culprit of an occlusion. 
SIPA clots were generated in a closed in vitro flow loop to investigate the SIPA 
clot structure. The size of the generated SIPA clot was physiologically relevant (2 mm in 
diameter and 5 mm in length) and had a trumpet-like shape with the mouth opened against 
the blood flow. SEM images showed that the platelets were tightly packed in the clot with 
a density of 0.1 platelets/µm2, indicating that the 1.23 billion platelets were aggregated in 
the SIPA clot. Even more platelets are expected to be present in the clot because the density 
was calculated by counting spheres (i.e., unactivated platelets) from images. The 
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histological images showed consistent results in which the clot was VWF-platelet-rich, and 
RBCs were trapped in the pores, which is strikingly similar to the SIPA clot formed in mice 
in vivo model in Ch2 (Figure 2-7D). Casa and Ku (2017) suggested a 7-step process for a 
SIPA clot formation. The process starts with a high wall shear rates (step 1) and VWF 
adsorption onto the collagen surface (step 2). In this study, the SIPA clot had a high VWF 
density on the wall, but sparse platelets compared to the lumen side. The plasma VWF 
must be important for the lag phase (step 1-2), as platelets need to be captured at the wall 
(step 3-4). 
Casa et al. (2016) found that plasma VWF is more important than platelets in 
forming occlusive SIPA clots. When a sufficient amount of VWFs are accumulated, and a 
minimum number of platelets are captured (step 3-4) and activated, platelets can make new 
highly reactive surfaces by releasing granules of VWF (step 5). As discussed in CHAPTER 
2, α-granules are necessary to initiate the RPA phase (step 5-7) and the subsequent vessel 
occlusion. The histological images show that there was a sudden transition from light blue 
to dark blue all the way to the lumen. This light blue layer was about 20 µm thick, which 
is comparable to the 10 µm thrombus thickness defined by Bark, Para, and Ku (2012) for 
the lag phase. Based on the growth rate of SIPA, they suggested 10 µm thrombus thickness 
as a transition threshold from the lag phase to the RPA phase. Between 20 µm thick layer 
and center of the lumen, mountain-like structures protruding from wall to the lumen were 
found in a half-cut SIPA clot (Figure 3-16) and Carstairs staining slice in a longitudinal 
direction (Figure 3-40). This structure was prominent at the upstream (L2-3), with RBCs 
trapped in valleys between mountains. Past studies also observed these SIPA clot structures, 
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which was referred as “fingers”  in expanded polytetrafluoroethylene vascular graft tubing 
(Wootton, Markou, Hanson, & Ku, 2001) and glass capillary tube (Para & Ku, 2013).  
It is interesting how these mountains (indicated in Figure 3-12, Figure 3-47, Figure 
3-50, Figure 3-52, and Figure 3-55) grew perpendicular to the flow and occlude a large 
(~2.5 mm in diameter) channel. The mountains appear to have been growing faster near 
the apex due to a higher shear rate that promotes thrombus growth rate (Mehrabadi et al., 
2016). The faster growth at the apex region can constrict the lumen, creating a larger 
recirculation area distal that may accumulate RBCs (L5), but proximal region (L2-3) 
continues to grow at a lower growth rate compared to the apex region. While the mountains 
protrude towards the lumen, platelets may aggregate in valleys where reactive surfaces 
exist. In addition, the platelet aggregates that were captured in valleys may extend 
downstream (L5). Later, the apex region occludes the channel and stops blood flow, which 
inhibits the proximal region to grow and occlude the channel. Fibrin may form at the pores 
when the SIPA clot occluded the lumen, thus lowering the shear rate and enabling the 
coagulation cascade to occur. These whole processes are illustrated in Error! Reference 
source not found.. 
It is critical to know the permeability and composition of a clot in order to 
effectively deliver the thrombolytic agent and lysis. High permeability of SIPA clot may 
allow convective drug transport through the inner clot  (Diamond, 1999). Although a drug 
could be transported to the center of the clot through the pores, tPA may not work due to 
lack of fibrins in a SIPA clot where the histological images only trace amounts of fibrin. 
Thus, perfusing a thrombolytic agent that reacts with VWF or platelet may be needed to 
dissolve a SIPA clot. 
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The clot permeability and mechanical strength from this study are useful values for 
designing thrombectomy devices. Current simulation model (Chitsaz, Nejat, & Nouri, 2018) 
and in vitro assays (Gunning et al., 2018; Khalil et al., 2017; Y. Liu et al., 2020) used only 
coagulation clots to test thrombectomy devices. The permeability of the SIPA clot can be 
used to simulate and design aspirational devices as they use fluid force to remove the 
arterial thrombi. The mechanical strength of the SIPA clot quantified in the present study 
could be used to optimize the wire based thrombectomy devices (e.g., stent and coil 
retriever).  
The present study had several limitations. First, only one animal’s (porcine) blood 
was used to generate the clot. However,  Para and Ku (2013) found there was no significant 
difference between human and porcine blood when generating a SIPA clot. In the future, 
it would be interesting to use human blood (e.g., from polycythemia vera patients for the 
large tube experiment) and compare the histology and mechanics results. Second, high 
shear chambers had rigid impermeable walls, and steady flow was applied for the SIPA 
clot generation. Different materials of walls (PDMS vs. glass) may have different stiffness 
and may differ in adsorption of hydrophilic compounds. Third, the breakage strength of 
the clots was estimated from pressure blow-out tests, but more direct measurement of 
tensile strength may be used to validate the results. Fourth, the brown color of VWF 
immunostaining in the clot was hard to distinguish from the RBCs (yellow). In the future, 
it could be interesting to use immunofluorescence staining to compare the relative 
dominance of VWF vs. fibrin in SIPA and coagulation clots. 
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Figure 3-90. Process of SIPA clot formation in a large glass tube. 
 
3.5 Conclusions 
A SIPA clot generated in an in vitro flow loop, was VWF-platelet-rich and had a 
heterogeneous structure. SEM images of the clot revealed densely packed platelets, which 
can be converted into 1.23 billion platelets in the clot. Whereas histological images showed 
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distinctive structural features for upstream, near the apex, and downstream of the stenosis. 
Upstream region showed mountain-like platelet aggregates protruding to the central lumen 
that left a large hole in the center, while RBCs trapped in valleys. Near the apex, dense 
platelet aggregates throughout the lumen fully occluded the channel. Unactivated platelets 
were present at the downstream end of the thrombus that ended abruptly and did not extend 
to the walls located in the flow separation zone. Compared to a coagulation clot, the SIPA 
clot was three orders of magnitude more permeable, but two-fold stiffer and seven-fold 
stronger which make it capable of occluding a stenosed coronary artery with a short clot 
length of less than 2 mm. Due to its distinctive mechanical properties, the SIPA clot may 
require a new thrombolytic agent and optimized thrombectomy devices for the treatment. 
 
3.6 Acknowledgements 
We thank Yolande Berta for her help with the sputter coating and SEM imaging of the 
SIPA clot and Aqua Asberry for her help with Carstairs staining. 
  
 104 
CHAPTER 4. THROMBOLYSIS OF ARTERIAL SIPA CLOTS 
4.1 Introduction 
An acute ischemic stroke because of an occlusive arterial thrombosis in the carotid artery 
can lead to a patient’s death. More than 700,000 cases of ischemic stroke occur in the 
United States every year (Mozaffarian et al., 2015; Prabhakaran et al., 2015). The primary 
goal of ischemic stroke treatment is to retain the blood flow in the brain by removing an 
occlusive blood clot. The current gold standard for stroke treatment is the use of the IV 
tPA within 3 hours of the onset of symptoms (Bivard et al., 2013; Prabhakaran et al., 2015).  
tPA catalyzes the conversion of plasminogen to plasmin, and plasmin cleaves fibrin 
(Bivard et al., 2013; Brenner, 1988). The cleavage of fibrins results in fibrin degradation 
product (Figure 1-3) and lysis of a fibrin-rich clot. However, SIPA clots in arteries are rich 
in VWF platelets and have less fibrin (Ku & Flannery, 2007). tPA has shown a limited 
recanalization rate of less than 30% (Bhatia et al., 2010) and a risk reduction of 30% 
compare to a placebo in stroke patients. In addition, there was no statistically significant 
decline in the overall mortality with the use of tPA (Chapman et al., 2014). tPA has a high 
rate of bleeding complications because of the induction of a hyperfibrinolytic state, which 
deters its clinical use (Crescente et al., 2012; Marder, 2011; Wechsler, 2011).  
Clot composition may determine the efficacy of a thrombolytic drug. As arterial 
thrombi are formed under high shear conditions and are VWF-platelet rich, tPA may not 
be an efficacious thrombolytic agent for SIPA clots. Therefore, we tested the efficacy of 
potential novel thrombolytic agents and tPA on SIPA clots. Potential thrombolytic agents 
that may react with SIPA clots are selected based on the literature.  
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A Disintegrin and Metalloproteinase with a Thrombospondin Type 1 Modtif, 
Member 13 (ADAMTS-13) is the protease that cleaves VWF, the main component of SIPA 
clot formation under high shear rates (Casa et al., 2016; Muia et al., 2014; Para, Bark, Lin, 
& Ku, 2011). Denorme et al. (2016) showed the potential thrombolytic use of ADAMTS-
13 in a mouse model of acute ischemic stroke. They induced arterial thrombosis by 
applying FeCl3 to mouse arteries. Abciximab is a GPIIb/IIIa inhibitor that blocks 
interactions between platelets and fibrin or VWF (Coulter Stephanie et al., 2000; Kwon et 
al., 2002). N-acetylcysteine (NAC) has been shown to cleave plasma VWF and prevent 
thrombosis (Chen et al., 2011). Furthermore, Martinez de Lizarrondo et al. (2017) 
demonstrated that NAC can be used as a thrombolytic agent for FeCl3-induced thrombi. S. 
M. Hastings and Ku (2017) reported that NAC lyses SIPA clot better than tPA, ADAMTS-
13, and Abciximab. However, NAC batches were found to have a high variability and the 
high-efficacy batches contained N,N’-Diacetyl-L-cystine (DiNAC). Therefore, we also 
tested DiNAC as a thrombolytic agent for SIPA clots.  DiNAC is the disulfide dimer of 
NAC that has been studied for its anti-atherosclerotic effects (Pettersson & Bergstrand, 








4.2.1 Capillary tube preparation 
The stenotic glass test sections (ID = 1.5 mm) were made by the Chemistry and 
Biochemistry Glass Shop at Georgia Institute of Technology. The percent stenosis by 
diameter reduction ranged from 60% to 80%. Capillary glass tubes were washed and reused 
multiple times after each experiment. The washing protocol is described as follows. 
I. Incubation in a sonicator for 15 min. 
II. Incubation in a hot chamber (130°C) or sterilization in a sterilizer. 
III. Repeat I and II, 2 times. 
IV. Drying in a hot chamber (70°C). 
4.2.2 Collagen coating 
Fibrillar equine collagen (type I; Chrono-Log Corporation, Havertown, PA) was diluted 
9:1 in NaCl (Sigma-Aldrich, St. Louis, MO) and incubated in the test section (10 µL each) 
at the stenosis for 24 h in a warm, moist environment(Para et al., 2011; Para & Ku, 2013). 
4.2.3 Blood collection 
Immediately following the slaughter, porcine blood was collected at a local abattoir into 
3.5 U/mL heparin (Thermo Fisher Scientific, Waltham, MA) or 3.2% sodium citrate 
(Sigma-Aldrich, St. Louis, MO). On the same day as the collection, WB was gently agitated 
using an Orbit LS shaker (Laboratory Supply Network, Atkinson, NH) until perfusion, and 
it was used in experiments as soon as possible. 
 107 
4.2.4 Syringe perfusion 
Lightly heparinized porcine WB was perfused through the stenotic test section using a 
syringe pump. The flow rate was set so that the initial wall shear rate in the stenosis was 
3,500 s-1. A pressure transducer was connected in-line upstream of the stenosis (Figure 
4-1A). A dissecting microscope with a camera (PCO-Tech Incorporated, Romulus, MI) 
was used to capture images in real time during perfusion. The upstream pressure increased 
as the SIPA clot grews at the stenotic section, and the syringe pump was paused when the 
pressure increase reached 30 mmHg, to perfuse the thrombolytic agent. In sequence, agents 
(tPA, ADAMTS-13, abciximab, NAC, and DiNAC) and a control treatment with PBS were 
perfused for an hour at a constant flow rate of 1 mL/min. Agent solutions were made by 
dissolution or dilution in PBS. The in vitro flow system setup and image acquisition are 
shown in Figure 4-1, and the concentrations of each agent are detailed in Table 5. Real-
time image capture (5 frames per second) of the stenosis and upstream pressure recording 
using LabVIEW (National Instruments, Austin, TX) continued throughout the experiment. 
Table 5. Thrombolytic agent concentration and replicate number. 
Agent Concentration Number of replicates 
DiNAC 0.02 mM, 0.2 mM, 2 mM, 20 mM, *20 mM 8, 8, 9, 8, 8 
NAC 2 mM, 20 mM 7, 5 
tPA 20 𝜇g/mL 4 
ADAMTS-13 1 𝜇g/mL 4 
Abciximab 35 𝜇g/mL 4 
PBS - 10 
    * Neutralized DiNAC solution  
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Figure 4-1. The in vitro perfusion system for creating platelet-rich, occlusive thrombi 
under arterial (high) shear rates, followed by perfusion of known and potential lytic 
agents. (A) Schematic of the arterial flow setup. (B) Close-up of the glass capillary 
tube with stenosis, which is coated with fibrillar collagen prior to perfusion. The red 
box denotes the region of interest. (C) Thrombus formation and subsequent perfusion 
with a PBS control, showing no lysis at the end of the experiment. 
4.2.5 Formation and lysis of coagulation clots 
PRP was made by separating citrated WB via gravity over a 2 h period and collecting the 
supernatant. Separation by gravity was employed instead of centrifugation to avoid platelet 
damage and activation. Citrated WB or PRP was then recalcified with CaCl2 to a final 
[Ca2+] of 10 mM (Griffin et al., 2019), and 200 µL was transferred into 500 µL centrifuge 
tubes and allowed to clot and retract for 30 min. The clot was then incubated with 100 µL 
of either agent or control solution. The treatment solution was exchanged by removing the 
top 100 µL and replacing it with a fresh solution at 3, 6, 12, 24, and 48 h of incubation. 
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The weight of the tube was measured immediately post-clot formation and each time the 
old solution was removed but before it was replaced with fresh solution. 
4.2.6 Computational Fluid Dynamics analysis 
CFD was used to calculate the drag force acting on the thrombi formed in the stenosis under 
flow. Simulations were performed using Ansys 19.1 (Ansys Inc, PA, USA).  WB was 
assumed to be a Newtonian fluid of 3.5 cP, and flow was presumed to be laminar, 
incompressible, steady, continuous, and isothermal because of the low Reynolds number 
(Re = 16). The capillary tube was modeled with no-slip walls, and a 1 ml/min flow rate 
was applied at the inlet, with zero-pressure at the outlet, reflecting experimental conditions. 
Mesh convergence was achieved at 3.8 million tetrahedral cells yielding a residual error of 
10-9. 
4.2.7 Data analysis 
The thrombi surface area (colored green) was calculated using manual pixel counting in 
the open-source GNU Image Manipulation Program (GIMP, Version 2.10.8, 1995-2018). 
Surface area reduction was calculated by percent pixel reduction versus the occlusion 
image. After checking normality of a data, analysis of variance (ANOVA) was used to test 
for statistical differences between groups, with the significance set at p < 0.05. Data are 





4.3.1 DiNAC lysed SIPA clots better than NAC 
NAC batches from multiple vendors showed large variability in thrombolytic efficacy on 
SIPA clots. To find the difference between batches, mass spectrometry was conducted on 
NAC solutions, and high-efficacy solution was found to have DiNAC. Therefore, DiNAC 
could be the potential thrombolytic agent that lyses SIPA clots. To test this hypothesis, low 
(2 mM) and high (20 mM) concentrations of pure NAC and DiNAC solutions were 
perfused over SIPA clots formed in our established stenotic capillary tube model. Figure 
4-2 and Figure 4-3 show the effects of DiNAC and NAC perfusion over 60 min on 
occlusive thrombi in the glass stenoses. In Figure 4-2, DiNAC dissolved most of the 
thrombi (> 95%) within 14 min with 2 mM and within 1.5 min with 20 mM. In contrast, 
NAC did not cause lysis at 60 min (Figure 4-3), leaving most of the thrombi (green) in the 
stenosis. The thrombus areas after a 60 min perfusion in the capillary tube were compared 
for DiNAC and NAC, and DiNAC showed a significantly higher reduction of thrombus 




Figure 4-2. Perfusion with DiNAC. The thrombus surface area was determined by 
pixel counting and is shown in paired images below originals, with the thrombus area 
highlighted in green. (A) 2 mM DiNAC perfusion showing complete (> 95 % surface 
area reduction) lysis in 14 min. (B) 20 mM DiNAC perfusion showing complete lysis 




Figure 4-3. Perfusion with NAC. The thrombus surface area was determined by pixel 
counting and is shown in paired images below originals, with the thrombus area 
highlighted in green. (A) 2 mM NAC perfusion, with minimal lysis (< 20 % surface 
area reduction) after 60 min. (B) 20 mM NAC perfusion after 60 min, again with 




Figure 4-4. Perfusion with DiNAC and NAC. (A) Thrombus area reduction over time.  
PBS is included as a negative control (black line).  (B) Thrombus area after 60 min 
perfusion with the indicated agent (x-axis). 2 mM and 20 mM DiNAC cause 
significantly more lysis than the control, while neither concentration of NAC was 
more efficacious than PBS. DiNAC also was significantly different from NAC at each 
concentration. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
4.3.2 Dose response of DiNAC 
DiNAC was tested with varying dosages of 0.02 mM, 0.2 mM, 2 mM, and 20 mM to 
confirm the efficacy. The result demonstrated an increasing reduction of the thrombus area 
as dosage increased (Figure 4-5). The final thrombus area was minimal at 2 mM (71 ± 
20%) and slightly increased at the highest concentration of 20 mM (59 ± 12%). However, 
this was not significantly different (p = 0.86). The lowest concentration of 0.02 mM 
DiNAC was not significantly different from the PBS control, but 0.2 mM showed a 
significantly decreased thrombus area (46 ± 15%, p = 0.02 < 0.05). The 20 mM DiNAC 
solution was found to be acidic (pH ≈ 2), while 2 mM DiNAC was close to neutral (pH = 
7). To test if acidity affected thrombolytic efficacy, the 20 mM DiNAC solution was 
neutralized with sodium bicarbonate to a final pH = 7. Neutralization of 20 mM DiNAC 
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improved the variance from 47% to 12% in surface area reduction (44 ± 47% vs 59 ± 12%, 
p = 0.77, Figure 4-5). 
 
Figure 4-5. DiNAC dosage response with concentrations of 0.02 mM, 0.2 mM, 2 mM, 
and 20 mM. The * denotes the acidic DiNAC 20 mM solution. (A) Thrombus area 
reduction over time. The control is shown in black. 0.02 mM DiNAC was not different 
from the control (yellow), and 2 mM DiNAC (orange) had the greatest efficacy. (B) 
Thrombus area after 60 min perfusion with increasing concentrations of DiNAC. 
Concentrations of 0.2 mM and greater were significantly different from the control. 
Neutralization of DiNAC mitigated variability and increased the surface area 
reduction (20 mM vs. 20* mM). * p < 0.05; *** p < 0.001; **** p < 0.0001. 
4.3.3 Thrombolytic efficacy of the other agents on SIPA clots 
A negative control with PBS for 60 min of perfusion reduced the thrombus surface area by 
9 ± 12% (Figure 4-1C). Perfusion with 0.02 mg/mL tPA reduced the thrombus surface area 
by 23 ± 4% (Figure 4-6A), demonstrating a weak thrombolytic effect compare to DiNAC. 
Perfusion with ADAMTS-13 reduced the thrombus area by 19 ± 8% (Figure 4-6B), and 
perfusion with Abciximab resulted in a reduction in thrombus area of 22 ± 11% (Figure 
4-6C). None of these three agents was significantly different from the PBS control (Figure 





Figure 4-6. Thrombolysis with the other agents. The thrombus area is highlighted in 
green. Perfusion with tPA (A), ADAMTS-13 (B), and abciximab (C) perfusion showed 
minimal lysis after 60 min. (D) Thrombus area reduction over time. (E) Thrombus 
area after 60 min perfusion with the indicated agent (x-axis). Perfusion of tPA, 
ADAMTS-13, and abciximab had no effect on the white clot, with no differences from 
the control. 
4.3.4 DiNAC does not lyse fibrin-rich coagulation clots 
We generated fibrinous coagulation clots by re-calcifying citrated WB (Figure 4-7) and 
PRP (Figure 4-8) under stagnant conditions, and agents were applied to quantify 
thrombolytic efficacy. PRP was included to test any potential platelet-specific interactions 
by agents. Only tPA showed significant thrombolytic efficacy on coagulation clots (Figure 
4-9). Between 6 h and 12 h, tPA began to show significantly reduced both clot volume and 
weight (p < 0.01) compared to the PBS control. At the end of the experiment (= 48 hr), tPA 
lysed more than 80% of both WB and PRP coagulation clots. Whereas, the other agents 




Figure 4-7. Lysis results on WB coagulation clots formed under stagnant conditions 




Figure 4-8. Lysis results on PRP coagulation clots formed under stagnant conditions 




Figure 4-9. Change of clot weight with WB (A) and PRP (B) clot in 48 h. tPA-lysed 
clots resulted in changes in weight significantly different from baseline after 6 h for 
WB (A) and 12 h for PRP (B) (26 % and 36 % reduction, respectively, **p < 0.01).  
DiNAC, NAC, and ADAMTS-13 had no effect on red clots, with no differences from 
baseline nor control. 
4.3.5 SIPA clot elongates and break during DiNAC perfusion 
DiNAC perfusion on the SIPA clot led to a break apart of thrombus in fragments. The 
initial fragments were smaller than the entire thrombus with some retained thrombus on 
the glass wall. Thus, it is not likely that the glass-collagen interface was the source of the 
initial weakness. The thrombi fragments were stretched downstream and towards the center 
of the lumen, away from the wall, and often remained tethered by a strand longer than 1 
mm at the stenotic region. The strand shaped thrombi remained tethered for several 
minutes, before eventual breakage (Figure 4-10A). 
The flow field around thrombi in the tube were simulated using CFD (Figure 
4-10B) to quantify the shear stresses and hydrodynamic drag forces on the fragments. The 
modeled thrombi fragments are colored in gray in Figure 4-10B. High-velocity jet-like 
flow was seen in the stenosis with recirculation downstream (Figure 4-10C). Maximum 
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shear rate occurred at the stenosis reached over 15,000 s-1 while shear rates of 
approximately 4,000-8,000 s-1 acted on the surface of thrombus downstream (Figure 
4-10D). The total drag force was 380 nN for the smaller fragment and 780 nN for the larger 
fragment (Figure 4-10E). A typical bond strength is on the order of 100 pN, thus, there 
needs to be many thousands of bonds to hold thrombi remain tethered. 
 
Figure 4-10. Simulation of flow and force through the stenosis using CFD. (A) 
Structure of a thrombus during elongation and breakage at 0, 15, and 30 minutes of 
DiNAC perfusion. Black arrows denote points of tether breakage. (B) Computer 
model of the attached thrombus fragments at 15 min. (C) Velocity streamlines 
showing a jet-like flow and recirculation downstream of the elongated thrombus 
colored in gray. (D) Shear strain rate around the thrombus. A maximum shear of 
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15,000 s-1 (red) was observed in the throat of stenosis. (E) Drag force acting on the 
thrombi surface. The thrombus 2 fragment experiences a maximum force of > 4 nN. 
 
4.4 Discussion 
Different thrombolytic agents were efficacious for different types of clots. Compared to 
the other agents, DiNAC showed a significantly high thrombolytic efficacy for SIPA clots. 
A disulfide bond between two NAC monomers forms DiNAC that has been studied for its 
anti-atherosclerotic effects (Pettersson & Bergstrand, 2003; Wagberg et al., 2001) but not 
for a thrombolytic effect. DiNAC reduced more thrombus area as its concentration 
increased from 0.02 mM to 0.2 mM and 2 mM, but it had slightly less efficacy at 20 mM. 
The acidic 20 mM DiNAC solution showed lower variability when neutralized with sodium 
bicarbonate. In the process of thrombolysis by DiNAC, a SIPA clot broke into multiple 
fragments, and some fragments elongated and floated in the flow while tethering to the 
surface. The thrombus fragments eventually detached, broken into smaller fragments, and 
washed away from the stenotic region. The length of a stretched thrombus was in the order 
of millimeters, which can be expected to be VWF strands. When a thrombus was stretched 
in the flow, the hydrodynamic drag acting on the surface was quantified to be 380 ~ 780 
nN. The bond strength of GPIb (T. Yago et al., 2008) and GPIIb/IIIa is on the order of 
~100 pN. Thus, many thousands of bonds are required for a thrombus to be tethered, and 
it is consistent with previous bond number estimates by Wellings and Ku (2012). On the 
other hand, DiNAC did not show any significant lysis if the coagulation clots. Thus, 
DiNAC may not cause severe bleeding, which has limited the use of tPA in patients. The 
limited effect of DiNAC on PRP clots suggests that DiNAC is not reacting with the 
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platelets, but it may be interacting with VWF or the VWF-platelet bond to achieve 
thrombolysis. 
 
Meanwhile, tPA showed a significant thrombolytic efficacy on WB and PRP 
coagulation clots compared to the other agents in this study. tPA lysed coagulation clots 
with an approximate front speed of 3.5 µm/min. This is comparable to the other in vitro 
fibrinolytic assays (Bannish, Chernysh, Keener, Fogelson, & Weisel, 2017; Tasci et al., 
2017). tPA breaks down fibrins by activating plasminogen into plasmin. Thus, this process 
requires the presence of endogenous plasminogen and it occurs within minutes of chemical 
reaction for the lysis (Hoylaerts, Rijken, Lijnen, & Collen, 1982; Piebalgs et al., 2018). 
Coagulation clots may form after a SIPA clot occludes an artery, thus it could be beneficial 
to co-administer tPA with DiNAC. 
SIPA clots were not lysed effectively by tPA, ADAMTS-13, Abciximab, or NAC. 
tPA may lyse SIPA clots better with additional plasminogen in the system. Tersteeg et al. 
(2014) suggested that plasmin is a potential back-up chemical for ADAMTS-13, and they 
showed that plasmin degrades platelet-VWF complexes. ADAMTS-13 is known to cleave 
ULVWF when it is stretched under high shear conditions (Crescente et al., 2012; Gurevitz 
et al., 1998). Furthermore, ADAMTS-13 has been shown to have potential antithrombotic 
and thrombolytic effects in vivo (Crescente et al., 2012; Denorme et al., 2016). In the clot, 
the VWF may be sufficiently stretched for ADAMTS-13 to access and cleave the VWF, 
but spatial obstruction might keep ADAMTS-13 (molecular weight 190 kDa) from 
penetrating the thrombus, compared with a small molecule like DiNAC (molecular weight 
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324 Da), as thrombus must be tightly packed with platelets and VWFs. Using an in vivo 
FeCl3 injury model, Crescente et al. (2012) found that both tPA and ADAMTS-13 reduced 
thrombus size (by 53.2% and 62.3%, respectively) after a 60-min treatment. They used a 
higher concentration of ADAMTS-13 (4 𝜇g/mL), which may account for the differences 
in our results. Because of the prohibitively high cost of ADAMTS-13, tests were limited 
to the concentration the level of ADAMTS-13 in normal plasma (1 𝜇g/mL ) (Soejima et 
al., 2006). Abciximab has shown synergetic effect when used with thrombolytic agents, as 
it blocks GPIIb/IIIa bonds and prevent platelet aggregation observed in patients treated 
with tPA (Coulter Stephanie et al., 2000; Kwon et al., 2002). However, no significant 
thrombolytic effect was found in this study with abciximab alone. As a future study, it 
would be interesting to test abciximab together with other agents. Currently, NAC is used 
to treat chronic obstructive lung disease by reducing the size of mucin multimers. VWF is 
very similar to the mucin multimers in structure (Chen et al., 2011; Perez-Vilar & Hill, 
1999) and Chen et al. (2011) confirmed VWF cleavage by NAC, motivating this study to 
use NAC as a potential thrombolytic agent for SIPA clot. Martinez de Lizarrondo et al. 
(2017) demonstrated the thrombolytic efficacy of NAC by using an in vivo mouse model. 
However, they found limited reperfusion of less than 40% with NAC alone. Other 
proteolytics (e.g., trypsin) can be tested in the current experimental set-up in future. 
There are limitations to this study. To transport blood from the abattoir and prevent 
any contact activation, a light heparin (3.5 IU/mL) was used as an anticoagulant. Heparin 
interrupts thrombin, so it does not disrupt the SIPA process, but it may affect coagulation 
downstream or in a recirculation region with low shear. Porcine blood can be different from 
human blood, but the difference is expected to be minimal (Mehrabadi et al., 2016). The 
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stenotic region was viewed from a top-down direction, and only 2-dimensional images 
were recorded. Thus, lysis of a thrombus was measured by quantifying area reduction. A 
3-dimensional imaging technique may produce new information about the reduction of 
thrombus volumetric or the initial lysis site inside the thrombus. The flow was paused 
before the thrombus became too occlusive to deliver agents efficiently. Delivery of DiNAC 
(e.g., IV, oral, and catheter infusion) is left for a future study. When switching the syringe, 
there is mixing between agents and blood, but a limited supply of blood plasma may 
constrain thrombolytic efficacy of tPA (plasmin) or ADAMTS-13 (ions). As a future study, 
using an in vivo mouse model could be beneficial, since it uses conditions that are closer 
to clinical circumstances and the toxicity of the agent can be quantified. In addition, 
clarifying the mechanism behind the thrombolytic efficacy of DiNAC is remains for future 
study.  
4.5 Conclusion 
DiNAC was highly efficacious in the lysis of SIPA clots created in an in vitro stenotic 
coronary artery model perfused under high shear stress. DiNAC demonstrated significantly 
higher thrombolytic efficacy than NAC and other agents in this setting, including tPA and 
ADAMTS-13. DiNAC was unable to lyse coagulation clots in a stagnant setting, while tPA 
was highly efficacious in the latter system. These results indicate the possibility of DiNAC 
as an effective thrombolytic agent against arterial thrombosis without the side effects of 
severe hemorrhage associated with current thrombolytic therapies. 
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CHAPTER 5. CONCLUSIONS AND FUTURE WORK 
A combination of in silico, in vitro, and in vivo methods were used to investigate the role 
of α-granule on SIPA clot formation. To initiate the RPA phase and induce SIPA under 
high shear condition, α-granule release from platelets was necessary. Among many 
chemicals in an α-granule cargo, VWF is expected to play an essential role under high 
shear conditions. Thus, it would be interesting to explicitly study platelet VWF by 
developing and using genetically modified mice. Also, it would be interesting to perfuse 
GPS patient’s blood in the microfluidic assay to confirm the Nbeal2-/- mice experiment 
results. Lastly, α-granule could be a potential new target for pharmacological interventions 
to prevent SIPA clot formation in myocardial infarction or stroke patients. In the past, 
membrane-active drugs (e.g., chloroquine, hydroxychloroquine, camoquine and 
quinacrine) have been studied to prevent platelet α-granule release (Prowse, Pepper, & 
Dawes, 1982). These drugs can be tested through in vitro and in vivo models in this study 
and see if it prevents SIPA clot and has less bleeding complication compared to current 
antithrombotic agents (e.g., aspirin, abciximab, and clopidogrel). 
SIPA clots were fabricated in in vitro flow loops to investigate the structure and 
quantify mechanical properties: permeability, breakage strength, and modulus. SIPA clot 
was VWF-platelet-rich and had pores where RBCs are trapped. The SIPA clot was three 
orders of magnitude more permeable, but two-fold stiffer and seven-fold stronger than the 
coagulation clot. Based on measured breakage strength, calculation showed that the SIPA 
clot is capable of resist and occlude a stenosed coronary artery within 2 mm clot length. 
Due to its distinctive properties, the SIPA clot may require a new thrombolytic agent and 
optimized thrombectomy devices for the treatment. A large SIPA generated in a closed in 
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vitro flow loop could be useful to study heterogeneity, to perform a tensile test, and to test 
thrombectomy devices. It can also be used to see how SIPA clot’s mechanical properties 
change within various chemical environments (e.g., thrombolytic agent). The quantified 
mechanical properties can be used to perform fluid-structure interaction (FSI) simulation 
to study how does the SIPA deform and fracture under arterial flow condition. 
 DiNAC demonstrated a high thrombolytic efficacy on VWF-platelet-rich SIPA clot 
that was generated in an in vitro stenotic coronary flow model. DiNAC showed 
significantly higher efficacy than the other thrombolytic agents: NAC, tPA, ADAMTS-13, 
and abciximab. Meanwhile, DiNAC did not lyse fibrin-rich coagulation clots, whereas tPA 
lysed the clots significantly. Thus, DiNAC has the potential to be an effective thrombolytic 
agent against arterial thrombosis without the side effects of severe hemorrhage associated 
with current thrombolytic therapies. The next step would be to test DiNAC in an in vivo 
mice model to confirm the thrombolytic efficacy, to estimate bleeding risk, and to assess 
toxicity. The present study focused on efficacy evaluation; thus, the delivery and 
mechanism of DiNAC remain as future work. Lastly, a combination of multiple 
thrombolytic agents could be an interesting subject for future study. After the vessel 
occlusion, the coagulation clot may form at each end of SIPA clot due to a stagnant flow 
condition. Thus, coadministering DiNAC and tPA could be beneficial for a particular 
clinical situation.  
  
 127 
APPENDIX A. FOLTS-LIKE ARTERIAL STENOSIS MODEL 
Adapted from Folts, Crowell, and Rowe (1976) with input from the Di Paola Lab. 
METHODS 
I. Pre-procedure 
a. Anesthesia solution: Make cocktail of ketamine (100 mg/mL), xylazine 
(100 mg/mL), saline with 1:0.1:8.9 ratio. 
b. Measure the weight of the mouse. 
II. Anesthesia 
a. Grasp back of the mouse’s neck. 
b. Do IP (Intraperitoneal) injection based on the mouse’s weight (0.1 mL/10g) 
*Caution: Air bubbles in the syringe can kill the mouse. Remove air bubbles 
before the injection. 
c. Leave it for 5~10min. 
d. Clip the tail to check if the mouse is still awake. 
e. If the mouse reacts, wait for another 5 min or inject more anesthesia. 
*Caution: Too much anesthesia can kill the mouse. 
III. Dissection 
a. Place mouse on its back. Fix mouse’s legs. 
b. Cut skin around the neck. 
c. Remove fat and muscles to expose carotid artery.  
The carotid artery is located at right next to the white colored throat 
(0.5~0.6 mm in diameter). 
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IV. Isolation 
a. Carefully find carotid artery using forceps. 
b. Remove fat and nerves around the artery. 
*Fat and nerves can interrupt flow measurement. 
c. Place forceps below the artery. 
d. Place a silk thread on the tip of the forceps. 
e. Pull the thread and make a loose knot. 
V. Flow probe placement 
a. Place a flow probe on the artery. 
b. Put saline on the probe if it’s necessary. 
c. Check the flow rate (0.3~0.8 mL/min). 
*If the flow rate is too low or negative, remove the probe and check the 
artery. Remove fat around the artery if it is necessary. 
d. Wait around 2 min for the flow stabilization. 
VI. Suture stenosis 
a. Carefully tighten the knot.  
b. Wait ~2 min for the flow stabilization. Go for 75% first, wait, then for 50%. 
c. Check flow rate if it’s 50% of initial flow rate. 
*If the flow went below 0, untie the knot. 
d. Repeat A to C. 




VII. Mechanical injury 
a. Crush the vessel using forceps. 
b. Make sure flow rate at least goes down to 0 mL/min. 
c. Repeat 3 times. 
VIII. Post-process 
a. Collect the vessel (and the clot) if it is necessary. 
b. Euthanasia the mouse. 
c. Save the flow rate data.  
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APPENDIX B. SIPA CLOT GENERATION PROTOCOL 
MATERIALS: Heparinized blood (3.5 U/mL) 450 mL. 
METHODS 
I. Collagen coating 
a. Collagen solution: Make cocktail of collagen and saline with 1: 9 ratio. 
b. Place 60 µL of collagen solution on stenosis of the large glass tube. 
c. Make a mark on the large glass tube and leave it stationary in a container 
for 1 hour. 
d. Rotate the tube 180 degree and leave in the container for 23 hours. 
 
Figure B - 1. A large glass tube with collagen solution placed at the stenosis. 
II. Flow loop set-up 
a. Take out the large glass tube and flush with PBS. 
b. Connect the large glass tube to tubings. 
c. Set roller pump’s flow rate to zero. 
III. Blood preparation 
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a. Filter the blood to avoid any emboli in the circuit. 
b. Put blood in a 500 mL beaker. 
IV. Blood perfusion 
a. Put inlet tube into the 500 mL beaker (lower reservoir). 
b. Slowly increase the roller pump flow rate to fill the upper reservoir. 
c. Raise the outlet tube to avoid any bubble formation. 
d. Put outlet tube into the lower reservoir. 
e. Adjust the flow rate to achieve constant pressure gradient (constant blood 
volume at the upper reservoir). 
 
Figure B - 2. A closed in vitro flow loop set-up. 
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f. Lower down the flow rates every ~2 min as thrombus grow in the large glass 
tube. 
 
Figure B - 3. Growing SIPA clot at a large glass tube. 
g. When the flow rate is lower down to the minimum flow rate (5 mL/min), 
turn off the pump and leave the circuit 30 min ~ to achieve a complete 
occlusion. 
 
Figure B - 4. An occlusive SIPA clot formed in a large glass tube. 
V. Clot retrieval 
a. Drain blood from the circuit. 
b. Lightly flush the large glass tube with tap water. 
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Figure B - 5. A large glass tube after drain. 
c. Inspect the circuit for any blood clot formation. 
d. With a needle, detach transparent sheets at upstream and downstream. 
e. Put the needle between clot and large glass tube wall and swirl to detach the 
clot from the large glass tube. 
f. Retrieve the clot using forceps. 
 
Figure B - 6. A retrieved SIPA clot. 
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